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ABSTRACT 
 
Amyotrophic Lateral Sclerosis (ALS) is a fatal neuromuscular disorder caused by 
degeneration of motor neurons (MNs) in the spinal cord, brainstem, and cortex.     
It belongs to a group of heterogeneous disorders called “motor neuron diseases”, 
in which ALS is the most common form in adults. The progressive MN 
degeneration leads to a gradual muscle atrophy and paralysis. Patients affected by 
ALS usually die 3-5 years after the onset of symptoms due to respiratory failure.  
Up to now, no effective cure is available for ALS beyond supportive care and 
Riluzole, which only modestly prolongs survival.  
In the early stage of the disease, MN loss and consequent muscle denervation are 
compensated by axonal sprouting and reinnervation by the remaining MNs, but this 
mechanism is insufficient in the long term.  
Thanks to their multiple beneficial mechanisms, stem cell transplantation 
represents a promising therapeutic strategy for ALS and other neurodegenerative 
disorders. In fact, transplanted stem cells can provide therapeutic effect by 
modulating the micro-environment through the production of neurotrophic factors, 
eliminating toxic molecules, reducing neuroinflammation and generating auxiliary 
neural networks. Moreover, stem cells can eventually replace degenerating cells.  
A novel source for stem cell transplantation consists in the reprogramming of adult 
somatic cells into induced pluripotent stem cells (iPSCs). Since iPSCs are directly 
derived from adult tissues, they bypass ethical issue of the embryo manipulation 
and are patient-specific, potentially reproducing ALS features in vitro. This means 
that they are a promising tool for stem cells transplantation and to model human 
pathologies in vitro.  
In this study, we isolated a specific subpopulation of neural stem cells (NSCs) 
derived from differentiated iPSCs. Compared to other types of stem cell, NSCs are 
particularly appropriate for ALS treatment due to their peculiar ability to differentiate 
into neurons, astrocytes and oligodendrocytes.  
The rationale of this study consists in the selection of a subpopulation of NSCs 
able to engraft and migrate through the nervous system parenchyma, to protect 
degenerating MNs and to improve ALS phenotype.  
We selected NSCs for the presence of three markers: Lewis X (or LeX), CXCR4 e 
β1 integrin. Lewis X is a glycoprotein marker of stem cells with a relevant role in 
cell adhesion and migration. CXCR4 is a chemokine receptor, which increases the 
sensitivity of the cells to be recruited by the host spinal cord that produces 
chemoattractant cytokines. β1 integrin is a subunit of VLA4, a receptor that allows 
cells to cross the blood-brain barrier, particularly in the presence of inflammation as 
in ALS animal models and human patients. In order to evaluate the ability of 
LeX+CXCR4+β1+ NSCs to engraft into the nervous system and to improve ALS 
phenotype, we performed intrathecal injection of these cells in the SOD1G93A 
mouse model. 
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Transplantation resulted in an efficient engraftment of the cells, which reached 
central nervous system bypassing blood brain barrier, and in the protection of MNs 
and their axons from degeneration.  
This determined a preservation of neuromuscular junction (NMJ) innervations by 
maintaining their integrity and inducing axonal sprouting. These beneficial effects 
on neuropathological phenotype correlated with a significant increased survival and 
improved neuromuscular function of transplanted SOD1G93A mice. 
We also demonstrated the beneficial effects of LeX+CXCR4+β1+ NSCs in a 
human in vitro model of ALS. When co-cultured with these cells, iPSC-derived MNs 
from ALS patients showed an improvement in terms of survival and axonal growth. 
We then analyzed the molecular mechanisms underlying NSC protection 
demonstrating that our NSC subpopulation exerted positive effects through 
neurotrophic factors production, inhibition of the GSK3β activity, and limiting 
astrocytes proliferation through activation of vanilloid receptor.   
The results of this study suggest that effective protection of MNs and NMJs can be 
achieved targeting multiple deregulated cellular and molecular mechanisms in both 
MNs and glial cells in ALS models. 
This is particularly relevant for ALS because different pathological mechanisms 
likely contribute to its onset, making NSC transplantation a promising therapeutic 
approach for ALS. 
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1. INTRODUCTION  
 
1.1 Amyotrophic Lateral Sclerosis  
 
1.1.1 Clinical features  
Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressive and invariably 
fatal neuromuscular disorder. Also known as Lou Gehrig’s disease for the 
famous baseball player who died of this disorder, ALS is characterized by 
gradual degeneration and death of motor neurons (MNs), the nervous cells 
that control links between the nervous system and muscles [1]. In ALS, 
both upper MNs in the cortex and lower MNs in the spinal cord die, 
stopping sending messages to muscles. This leads to a progressive muscle 
weakness, atrophy and paralysis in few years [2] (Fig. 1).  
 
Fig.1 Illustrative comparison between healthy and ALS MNs. 
In ALS, spinal MNs are characterized by degenerating nerves, which cannot send message 
to muscles, causing their atrophy and paralysis. 
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The ALS belongs to a group of heterogeneous pathologies called “motor 
neuron diseases”, in which ALS is the most common and severe form in 
adults [3]. Patients affected by ALS usually die 3-5 years from the onset of 
symptoms due to respiratory failure [4], and only the 35% of patients 
survive 5 years or more [5].  
The term “Amyotrophic” is referred to the muscle atrophy, whereas “Lateral 
Sclerosis” is referred to the hardness to palpation of the lateral columns of 
the spinal cord in autopsy specimens [6]. The typical onset of ALS consists 
in an asymmetric weakness in a limb that causes unexplained foot drop 
and falls [6, 7]. Weakness rapidly spreads to contiguous limb regions and 
finally reaches respiratory muscles [8]. For this reason, ALS patients 
progressively lose their muscle strength and the ability to move their arms, 
legs and body. When paralysis reaches the diaphragm and chest wall, 
patients lose the ability to breathe without ventilatory support.  
Although approximately 65% of ALS cases are known as “spinal forms” 
with the initial involvement of the limbs, often asymmetric, the 30% of cases 
are “bulbar forms”, in which the ALS starts with dysarthria or dysphagia. 
Only 5% of ALS cases begin aggressively with early respiratory failure [9, 
10]. ALS usually does not affect cognitive functions, even if a subset of ALS 
patients has also a frontotemporal dementia or a subtle frontal lobe deficit. 
Also sight, hearing, taste, smell and touch are not compromised in ALS.  
Until the late stages of the disease, patients usually maintain control of eye 
muscles and functions of bladder and bowel [11]. The reasons of this 
relative sparing are unknown. Patients with ALS show a wide combination 
of symptoms and signs (Fig. 2) due not only to the site of onset, but also to 
the rate of ALS progression and the relative number of upper and lower MN 
deficits [8].  
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As a result of upper and lower MNs degeneration, clinical examination 
reveals a combination of upper MNs signs such as spasticity, hyperreflexia, 
hypertonia, extensor plantar response (or Babinski sign) and lower MN 
signs that include muscle atrophy, weakness, fasciculations and cramps 
[12].  
The propagation of ALS through the nervous system is not fully elucidated. 
It has been hypothesized that the focal damage of a localized group of MNs 
spreads to adjacent MNs [13], however is not clear whether ALS onset is 
primarily in the upper or lower MNs.  
The vast majority of ALS cases is sporadic (sALS), with no prior family 
history, and only a 10% of ALS cases are inherited or familial (fALS), 
usually as dominant traits [14]. The incidence of ALS is 2.16 per 100.000 
person/years [15] and there is no relevant difference between countries 
[16]. The lifetime risk of ALS is approximately 1:400 for women and 1:350 
for men [17]. The peak incidence occurs between 58-63 years for sALS and 
47-42 years for fALS, decreasing rapidly after 80 years of age [18]. 
Currently, there is no cure for ALS beyond supportive care and Riluzole, a 
putative glutamate release blocker that modestly prolongs survival. 
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Fig. 2 Schematic representation of ALS symptoms. 
Classification of ALS symptoms according to their onset, which could be bulbar or limb, and 
the type of MNs involved, which could be upper in cortex or lower in spinal cord. 
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1.1.2 Aetiopathogenesis  
 
Despite several studies aim at elucidating the ALS causes, the 
aetiopathogenesis is still unclear. In fact, ALS is a complex disorder 
involving an intricate combination of events including common and rare 
genetic, environmental and lifestyle factors [17]. 
The vast majority of ALS cases are sporadic (sALS), without a clear genetic 
linkage. Only the 10% of cases show familial inheritance, and are defined 
familial ALS or fALS [19]. However, the boundaries between fALS and 
sALS cases are undetermined due to the existence of sporadic cases 
associated with mutations in the same genes of familial ALS patients [5]. 
Furthermore, because ALS is a disease of the adulthood, the collection of 
large pedigrees suitable for linkage studies is often difficult, complicating 
the identification of ALS causative genes. 
 
Genetic causes   
The involvement of genetic factors in ALS occurs at various levels and now 
is identified in up to two-thirds of familial cases and 10% of apparently 
sporadic ALS. The genes involved in ALS frequently lead to a classic 
autosomal dominant pattern of inheritance, but can also be recessive or    
X-linked. Moreover, there are susceptibility genes that might enhance the 
risk of developing a sporadic form of the disease [5]. 
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The most significant causative genes include: 
 
- SOD1: it was the first causative gene of ALS identified. Discovered in 
1993 by Rosen et al., SOD1 gene encodes for copper/zinc ion-binding 
superoxide dismutase 1, an antioxidant enzyme that protects cells from the 
toxic effects of free radicals [20]. Alterations in SOD1 are particularly 
frequent and linked to 20% of ALS cases and 3% of apparently sporadic 
disease [21]. To date, more than 170 mutations have been reported along 
the peptide sequence of SOD1, causing a misfolding and aggregation of 
the mutant protein [22]. The mutant misfolded SOD1 is targeted for 
degradation through ubiquitylation; however, it escapes this regulatory 
process in the cell, gaining novel and toxic functions that leads to MN 
degeneration [23].  
Many different toxic mechanisms of mutant SOD1 have been suggested 
such as excitotoxicity [24], oxidative stress [25], failure of glutamate 
transporter [26], protein aggregation [27], aberrant protein-protein 
interactions [28], apoptosis [29], low binding affinity of zinc [30], 
mitochondrial dysfunction [31] and endoplasmic reticulum stress [32]. 
Interestingly, recent discoveries reveal that in some sALS patients, 
changes in oxidation, demetallation and other post-translational 
modifications occur, inducing aberrant conformations of wild-type (WT) 
SOD1. This leads to acquisition of toxic functions comparable to those of 
fALS patients with SOD1 mutations [33]. This finding suggests a role for 
WT SOD1 in sALS, possibly after oxidative modification. 
The phenotype is very similar among patients with mutations in SOD1, 
even though the onset and progression can be different depending on 
alternative SOD1 mutations [34].  
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- C9orf72: recently discovered in 2011 [35, 36], the alteration in C9orf72 
gene consists in a hexanucleotide repeat expansion of GGGGCC in a non-
coding region of chromosome 9 open reading frame 72 (C9orf72).             
The C9orf72 repeat expansion represents the most common genetic cause 
of fALS (30-50%) and it is also reported in a significant percentage of 
apparently sporadic ALS cases (4–10%) [36, 37]. Moreover, the 
(GGGGCC)n repeat expansion in C9orf72 determines many familial 
frontotemporal dementia (FTD) cases (~25 %), explaining the overlap 
between ALS and FTD [38, 39]. The normal number of GGGGCC repeats 
in healthy persons is between 2 and 23 repeats, patients with ALS and FTD 
show a range of 700 to 1600 repeats [35, 36]. 
The function of the protein encoded by C9orf72 gene is still unknown; 
however, the molecular mechanisms that underlie C9orf72-associated ALS 
are rapidly emerging [40]. In particular, three potential pathogenic 
mechanisms have been postulated: (1) loss of function owing to reduction 
in the transcript levels of C9orf72 mRNA variants in cells and tissue of ALS 
patients that may cause defects in autophagic and endosomal processes 
and MN function [36, 41-44]; (2) gain of RNA toxicity due to sense 
(GGGGCC) and antisense (GGCCCC) transcripts that accumulate in RNA 
foci and sequester critical RNA-binding proteins [36, 44-47];                   
(3) proteotoxicity from 6 dipeptide repeat proteins (DPR) produced by an 
unconventional form of translation (RAN translation) of the expanded 
repeat [48-51]. These DPR proteins are generated by translation in all 
frames of the GGGGCC repeat resulting in polymers rich of glycine-alanine 
(GA), glycine-proline (GP), glycine-arginine (GR), glycine-proline (GP), 
alanine-proline (AP) and proline-arginine (PR).  
C9orf72-related ALS patients have a wide range of phenotypes and also 
the age at onset vary between studies [52].  
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- TARDBP: also known as TDP-43, it encodes for a DNA and RNA binding 
protein. Its target sequences are mainly intronic and rich in UG sequences, 
but also include non-coding RNAs and 3′ UTRs [53]. In line with this, TDP-
43 plays a role in nuclear RNA metabolism including gene splicing [54], 
transcription regulation, processing of small regulatory RNAs (microRNAs), 
mRNA nucleo-cytoplasmic shuttling and RNA transport [55]. To date, the 
vast majority of mutations in TDP-43 are localized in the C-terminal domain, 
which is involved in binding other hnRNPs and is important for the splicing 
activity of TDP-43 [56]. TARDBP mutations have been found in 4-6% of 
fALS cases without SOD1 mutations and may be responsible for a small 
percentage (0.2%) of sALS patients and FTD [57]. 
Following the discovery of SOD1 aggregates, a breakthrough was achieved 
with the identification of TDP-43 as a major component of ubiquitinated 
inclusions in FTD and ALS cases [58]. Inclusions of TDP-43 are also found 
in ALS patients without TDP43 mutations; in fact, non-mutated TDP-43 
forms aggregates in all sALS patients and the vast majority fALS SOD1 
negative, but not in SOD1 related ALS [59].  
It is difficult to establish clear correlation between phenotype and genotype 
and is clinically impossible to discriminate TDP-43 patients from other ALS 
patients [16]. The onset of symptoms in TDP-43 patients can vary from 20 
to 77 years old [60]. 
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- FUS: it encodes for a RNA binding protein named fused in sarcoma. Like 
TDP-43, it is involved in RNA splicing, transport and translation, genomic 
maintenance, and transcription factor regulation. It has also a role in 
microRNA processing [57]. FUS mutations have been found in 4-6% of 
fALS and 0.7-1.8 of sALS cases [61]. Mutations in TDP-43 and in FUS, 
both involved in RNA metabolism, have focused the attention on the roles 
of this altered process in the development of ALS pathology. However, it 
remains unclear if the toxicity in mutant FUS cases is due to abnormal RNA 
modulation and metabolism, or to an altered localization of the protein in 
the cell [62]. 
 
Other genes are associated with a minor proportion of ALS patients               
(Table 1), while the vast majority of patients diagnosed with ALS are 
negative for mutations in known genes and up to now are considered as 
having a sporadic disease.  
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Table 1. Minor genes involved in ALS  
Minor ALS 
genes            Protein Function 
ANG Angiogenin Blood vessels formation 
OPTN Optineurin Vescicular transport 
UBQLN2 Ubiquilin-2 Proteasome 
DCTN1 Dynactin 1 Cytoskeleton dynamics 
ALS2 Alsin 2 Endocytosis 
CHMP2B Charged Multivesicular Body Protein 2B Vescicular transport 
FIG4 Phosphoinositide 5-phosphatase Vescicular transport 
HNRNP-A1 / A2B1 Heterogeneous nuclear ribonucleoprotein A1 and A2/B1 RNA metabolism 
SETX Senataxin RNA processing 
SPG11 Spastic paraplegia 11 DNA damage 
VAPB Vesicle-associated membrane protein-associated protein B Vescicular transport 
NEFH Neurofilament heavy Cytoskeleton dynamics 
ARHGEF28 Rho Guanine Nucleotide Exchange Factor 28 RNA metabolism 
SQSTM1 Sequestosome 1 Ubiquitination dynamics 
VCP Valosin containing protein Vescicular transport 
PFN1 Profilin 1 Cytoskeleton dynamics 
PRPH Peripherin Cytoskeleton dynamics 
DAO D-amino acid oxidase Neurotransmitter metabolism 
SIGMAR1 Sigma non-opioid intracellular receptor 1 Calcium metabolism 
TAF15 TATA-box binding protein associated factor 15 DNA damage 
ERBB4 Erb-2 receptor tyrosine kinase 4 Neural development 
MATR3 Matrin 3 Transciption dynamics 
TBK1 TANK-binding kinase 1 Apoptotic pathway 
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Environmental factors  
Several environmental factors have been proposed to be linked with ALS, 
but none of them are clearly established.  
Risk factors include pesticide contamination, metals, smoking, alcohol, 
lower body mass index, viral and fungal infections, head trauma, metabolic 
and inflammatory states, cancer and electromagnetic fields [63], as well as 
the exposure to unknown toxins, as detected among soldiers of Persian 
Gulf war [64]. Some studies have suggested a possible correlation between 
ALS and physical activity, because ALS incidence is higher in football and 
soccer players (respectively 40 and 6.5 fold), but this hypothesis has to be 
confirmed [65]. To date, the only established risk factors are older age, 
male gender and a family history of ALS [66]. In contrast, 
hypercholesterolemia, the use of statins and immunosuppressive drugs are 
associated with a decreased risk of ALS.  
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1.1.3 Animal models  
 
In order to extricate the entangled underlying pathomechanisms of ALS and 
test new therapeutics, a consistent number of animal models have been 
generated starting from knowledge on the genetic causes of ALS.  
ALS animal models include zebrafish, dog, drosophila melanogaster,         
C. elegans, and pig; however, the most used animals in pre-clinical trials 
are rodents (rats and mice).  
The first animal model that has been established for ALS is a transgenic 
mouse expressing multiple copies of human SOD1 gene with G93A 
mutation. This model develops a MN disease that recapitulates most of the 
clinical and neuropathological findings of familial and sporadic ALS [67]. 
SOD1G93A mice develop ALS symptoms at 80-90 days as shown by 
rotarod and hang-wire tests and they die at a median age of 140 days. 
However, it has been demonstrated that the degeneration of the 
neuromuscular junctions (NMJs) starts before the onset of symptoms, 
around 40 to 50 days [68]. Also the gliosis was found before onset of ALS 
and increased in intensity over time [69]. In addition to the original mutant 
SOD1G93A mice, a large number of other SOD1 transgenic mice have 
been created that include G37R (the second most used), G85R, D90A, 
G86R, mice with SOD1 truncated at the C-terminus. 
Most mice with SOD1 mutations represent human SOD1-associated ALS 
quite well. In fact, mice develop fatal paralysis with MN deficit, gliosis and 
SOD1 aggregates. However, these mice exhibit variable phenotypes, age 
of onset and survival that seem to be dependent on specific mutations, 
levels of mutant SOD1, gender and genetic background [16].  
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Despite a large number of attempts, the rodent models of TDP-43 are not 
perfect yet and none of these models is currently used for routine drug 
screening. These animals are characterized by varied phenotypes without a 
clear correlation between mutations and phenotypes, which is highly 
dependent upon the promoter used and the level of TDP-43 expression.     
In fact, low protein expression induces neuromuscular dysfunction and 
accumulation of TDP-43, but mice did not get paralyzed [70]. Vice versa, 
high expression of TDP-43 causes early onset and fast disease 
progression but without clear MN loss. In this case, death seems to be due 
to gastrointestinal complications rather than neurodegeneration [71].     
More recently, a promising TDP43 model is the double transgenic mouse, 
which expresses human TDP-43 wild type and human TDP-43 with Q331K 
mutation. This model recapitulates most ALS features in exclusion of age-
related degeneration [72].  
Up to now, different groups are working to generate a C9orf72 animal 
model. Despite these models did not recapitulate the pathology, C9orf72 
animal model are useful to understand the molecular mechanisms of 
C9orf72 expansion.  
For these reasons, the mutant SOD1 rodent models remain the best 
models currently available to study the pathogenesis of ALS and to test 
new therapies, although the question remains how to model sporadic forms 
of ALS [73].  
Moreover, some drugs established to be efficient in mice models have 
failed in clinical trials [74]. The causes for the failed translation of drug trials 
from animal models to humans can be due to several causes, including 
differences in drug penetration and metabolism that lead to a different 
biological response [75]. 
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1.1.4 Molecular mechanisms  
 
The basis of ALS are not entirely understood, and the molecular and 
cellular events involved in disease progression are various and complex.   
A wide spectrum of toxic molecular mechanisms has been proposed to 
mediate the progressive MN degeneration in ALS. Besides, to complicate 
matters further, different cell types, such as astrocytes, neurons, microglia 
and oligodendrocytes, contribute to the development of this pathology [76] 
(Fig. 3).  
 
 
Fig. 3 Representation of pathophysiological mechanisms underlying ALS. 
The mechanisms that underlie the development of neurodegeneration in ALS are 
multifactorial, with evidence of a complex interplay between genetic mutations and 
dysfunction of molecular processes.   
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The proposed molecular mechanisms of ALS include:  
 
Aggregation of toxic proteins  
Numerous WT and mutated proteins are dysfunctional in both sporadic and 
familial forms of ALS. Anomalies in physiological homeostasis of proteins 
are shown by presence of toxic aggregates, impaired degradation, 
abnormal cleavage events and distinctive post-translational modifications 
like ubiquitination and hyperphosphorylation [77].  
Aggregates of mutant proteins are hallmarks of neurodegenerative 
diseases, including ALS. Intracellular aggregates seem to alter the 
homeostasis of proteins and to determine cellular stress. It is hypothesized 
that these deposits sequester RNA and proteins essential for normal 
cellular function, impairing protein degradation and interfering with axonal 
transport. Moreover, the energetic exhaustion can be linked to the turnover 
of misfolded proteins [78]. Toxic deposits of protein are found in ALS 
patients and animal models and consist in aggregation of SOD1, TDP-43, 
FUS and DPR proteins. In particular, in the spinal cord of SOD1G93A mice 
model, SOD1 protein undergone to an abnormal/altered conformation, 
conventionally named as misfolded, which may explain its innate toxic 
nature [33, 79-81]. These aggregates occur both as primary consequences 
of protein mutations and as secondary phenomena due to the underlying 
disease process. However, it remains unclear if they are directly toxic or 
whether they reflect a cellular response. It has also been considered the 
possibility that some aggregates are beneficial and compensatory events 
[77]. 
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Non-cell-autonomous toxicity 
In ALS, the selective degeneration of MNs led researchers to focus on the 
mechanism within MNs. These mechanisms are known as cell autonomous 
mechanisms. However, recent discoveries reveal that also non-cell 
autonomous processes can significantly contribute to MN dysfunction and 
death [82]. In particular, astrocytes and microglial cells that surround MNs 
appear to play fundamental roles in ALS onset and progression [83]. 
Degenerating MNs release neurotoxic molecules that stimulate surrounding 
cells to produce reactive oxygen species and pro-inflammatory cytokines, 
resulting in MN damage and initiating the vicious cycle of progressive cell 
death [84]. Among the activated cells, astrocytes and microglia shift their 
function from anti-inflammatory and neuroprotective to pro-inflammatory 
and neurotoxic.  
Microglial cells, which are derived from the hematopoietic cell lineage, are 
the primary innate immune cells of the central nervous system. In ALS, 
microglial cells release reactive oxygen species, proinflammatory cytokines 
and other toxic substances, accelerating the MN death [85].  
Astrocytes, which are of neuroectodermal origin, do not belong to the 
immune system but may take part in the immune response, particularly in 
pathological states. In healthy condition, astrocytes produce neurotrophic 
factors that preserve and support neurons and maintain low concentration 
of glutamate removing the excess from the extracellular space [82]. In ALS, 
astrocytes lose their physiologically functions inducing neuronal death by 
loss of neurotrophins and reduced up-take of glutamate. Moreover, in vitro 
studies show that astrocytes release neurotoxic factors that can induce 
apoptosis in MNs. One of the identified toxic factors is neurotrophic growth 
factor [86].  
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Alteration of axonal transport  
An efficient axonal transport is critical event for neuronal function. There 
are well-demonstrated defects of axonal transport in both ALS animal 
models and human patients [87]. Researchers have identified mutations 
related to ALS in genes encoding for proteins directly involved in the axonal 
transport system [88, 89]. However, in the majority of ALS patients, altered 
axoplasmic flow is probably a secondary effect. Impaired axonal transport 
can be caused by alteration in key pathways, including the glycogen 
synthase kinase 3 beta (GSK3β) pathway. It has been demonstrated that 
GSK3β is a kinase that regulates neural polarization, neuritogenesis and 
axonal growth [90]. In ALS, GSK3β is overexpressed and hyperactivated 
inducing MN death. 
 
Oxidative stress and mitochondrial dysfunction  
There are substantial evidences implicating oxidative stress and 
mitochondrial dysfunctions as pathogenic mechanisms of ALS [91].          
While the first hypothesis proposed for SOD1 mutations suggested a 
primary role in oxidative stress related to its superoxide dismutase function, 
it is now presumed that the oxidative stress is only a secondary component 
of the pathogenesis.  
Post mortem tissues of ALS patients reveal clear signs of oxidative stress, 
as shown by a widespread accumulation of oxidative damage to proteins, 
DNA and lipids. Oxidative stress may cause several toxic effects such as 
formation of toxic misfolded protein, damage of mitochondria and activation 
of abnormal pathways [92]. Damages to mitochondria caused by oxidative 
stress induce alterations in morphology and function, resulting in energy 
deficit, calcium accumulation and activation of death pathways.  
Introduction 
 
18 
 
Among apoptotic pathways, the GSK3β pathway seems to be involved in 
neuronal degeneration. In fact, once activated, GSK3β induces activation of 
a series of substrates that causes apoptosis via cytocrome c caspase [93].  
 
Alterations of RNA metabolism  
A surprising number of proteins associated to ALS are directly or indirectly 
involved in RNA processing [94]. For this reason, currently the main theory 
to explain the aetiopathogenesis of ALS is referred to alterations in RNA 
metabolism [87]. This is due to the finding of mutations in genes encoding 
for DNA and RNA binding proteins, like TDP-43 and FUS, which are 
directly involved in every aspect of RNA metabolism, such as transcription, 
RNA splicing and transport, miRNA processing and translation [95]. 
Furthermore, one of the three molecular mechanisms postulated for 
C9orf72-associated ALS consists in toxic gain of function of abnormal 
messenger RNA. Expanded C9orf72 mRNA forms RNA foci that sequester 
critical RNA-binding proteins, which are then unable to correctly splicing 
other mRNAs [87]. Recently, a convergence of molecular pathways 
involved in RNA metabolism is emerging for ALS [96]. 
Although several advances in investigations has led to the identification of 
cellular and molecular processes involved in the MN degeneration, the 
understanding of the origin and progression of the ALS is still largely 
insufficient. 
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1.1.5 Therapeutic strategies  
 
The impact of ALS is tremendous not only on health and quality of life of 
patients, being severely disabling and fatal, but also on their family and 
society. For these reasons, ALS is associated with large unmet medical 
needs, in particular the urgency of an efficient, clinically meaningful 
therapy. To date, Riluzole is the only therapeutic drug approved by the U.S. 
Food and Drug Administration as a safe and well-tolerated treatment for 
patients with ALS. Riluzole is a benzothiazole anticonvulsant that reduces 
excitotoxicity by blocking voltage-gated sodium channels, with a 
consequent decrease in the pre-synaptic release of glutamate [97].  
Riluzole modestly prolongs survival by 2-3 months, delaying the use of 
supportive approaches, such as tracheostomy and mechanical ventilation. 
Because the beneficial effects of Riluzole are very modest with a small 
beneficial effect on both bulbar and limb function, but not on disease 
progression, effective treatments are urgently needed [98]. 
The knowledge of molecular and cellular mechanisms underlying ALS can 
be useful to develop an effective cure for this fatal disorder. The therapeutic 
strategies under development for ALS can be divided in pharmacological 
approaches, gene and cellular therapies (Table 2).  
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Table 2. Therapeutic strategies for ALS 
Compound Type of approach Target 
Mechanism of 
action Phase 
Dexpramipexole Pharmacological   (small molecule) Mitochondria 
Reduction of oxygen 
consumption III failured 
Rasagiline Pharmacological   (small molecule) Mitochondria 
Enhancement of 
mitochondrial viability II 
Fingolimod Pharmacological   (small molecule) T cells 
Blocking of T cells in 
lymph nodes II 
NP001 Pharmacological   (small molecule) Macrophages 
Reduction of 
macrophage activation II 
Tocilizumab Pharmacological   (antibody) Macrophages 
Reduction of 
macrophage activation II 
Lithium 
Carbonate 
Pharmacological   
(small molecule) 
Autophagic 
cells 
Boosting of 
autophagy-clearing 
misfoled proteins 
II 
Masitinib Pharmacological   (small molecule) Mast cells 
Blocking of cytokine 
production and mast 
cell migration 
III 
Fasudil Pharmacological   (small molecule) 
Astroglial and 
microglial 
cells 
Reduction of astroglial 
and microglial cell 
infiltration 
II 
Ozanezumab Pharmacological   (antibody) NMJs 
Repairing of motor 
nerves and muscle 
fibers 
II 
Tirasemtiv Pharmacological   (small molecule) 
Fast skeletal 
muscles 
Modulation of  muscle 
contractility III 
Ibudilast Pharmacological   (small molecule) Glial cells 
Suppression of glial 
cell activation II 
RNS60 Pharmacological   (small molecule) 
Neurons and 
glia 
Reduction of 
inflammation 
II 
Tamoxifen Pharmacological   (small molecule) Neurons 
Enhancement of 
autophagy pathway I/II 
Memantine Pharmacological   (small molecule) Neurons 
Reduction of 
excitotoxicity II 
Retigabine Pharmacological   (small molecule) Neurons 
Reduction of 
excitability 
II 
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Compound Type of approach Target 
Mechanism of 
action Phase 
BIIB067         
(Isis-SOD1Rx) 
Gene therapy 
Neurons and 
glia 
Reduction of 
misfolded SOD1 I 
Antisense 
C9orf72 
Gene therapy 
Neurons and 
glia 
Reduction of C9orf72 
inclusions Preclinical 
Glial restricted 
progenitor cells  
(Q Cells) 
Cell therapy Astrocytes Replacement of toxic 
astrocytes 
I/II 
Bone Marrow 
Derived Stem 
Cell 
Cell therapy Neurons and glia 
Cell replacement and 
micro-environmental 
enrichment 
I/II 
Adipose 
Derived 
Mesenchymal 
Stem Cells 
Cell therapy Neurons and 
glia 
Cell replacement and 
micro-environmental 
enrichment 
I 
Neural Stem 
Cells 
Cell therapy Neurons and glia 
Cell replacement and 
micro-environmental 
enrichment 
II 
 
 
Pharmacological approaches 
Pharmacological approaches include antibodies and small molecules that 
act on different targets with different molecular mechanisms of action. 
These drugs can be therapeutic via mitochondria protection, reduction of 
neuroinflammation and inhibition of kinase involved in aberrant pathways. 
Some of them, such as Masitinib and Tirasemtiv, are now in phase III 
clinical trial, or have been recently tested like Dexpramipexole 
(www.clinicaltrials.gov).  
Dexpramipexole reduces MN death by inhibiting aberrant mitochondrial 
leak conductance. Although Dexpramipexole seems to have positive effects 
in the phase II trial, the phase III study revealed an inefficacy of 
Dexpramipezole on survival, improving symptoms and disease progression. 
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The negative phase III results suggest that the phase II clinical trials for 
ALS might need to be redesigned (ClinicalTrials.gov Identifier: 
NCT01281189).  
Masitinib is a c-kit tyrosine kinase inhibitor, already evaluated to treat a 
wide range of diseases, including multiple sclerosis, Alzheimer’s disease 
and some types of cancer. The inhibition of c-kit, a stem cell factor 
receptor, causes a block of the proliferation and activation of mast and 
microglial cells. A phase III study is now ongoing and the interim results 
seems positive (ClinicalTrials.gov Identifier: NCT02588677). 
Tirasemtiv is a selective troponin activator that directly modulates the 
contractility of muscles, increases the strength of different skeletal muscles, 
particularly those crucial for breathing. Tirasemtiv resulted to be safe and 
tolerated in phase II clinical trial and a phase III is now ongoing 
(ClinicalTrials.gov Identifier: NCT02936635). 
 
 
Gene therapy 
A different approach to treat ALS consists in the injection of short synthetic 
and chemically modified nucleic acid that binds to an mRNA target, 
interfering with its function. This approach known as molecular therapy is 
now ongoing in clinical trials for several disorders (www.clinicaltrials.gov). 
For ALS, a possible gene therapy consists in delivery of antisense 
oligonucleotides to reduce the expression of toxic/misfolded proteins, such 
as SOD1 and C9orf72 [46, 81, 99].  
Pre-clinical studies performed on rodent model of ALS have been showed a 
reduction of SOD1 aggregates and increased survival after the treatment 
with an antisense oligonucleotide that targets SOD1 gene. 
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This antisense oligonucleotide (ISIS-SOD1RX) is now tested in phase I 
clinical trial in patients with SOD1-associated fALS through intrathecal 
administration into the spinal cord. This therapy reduces SOD1 levels and 
seems to be safe and tolerable [99]. 
To treat C9orf72 repeat expansion, preclinical studies with antisense 
oligonucleotides are now ongoing [46]. 
 
 
Cell Therapy 
Cell therapies are receiving increasing interest as tool to treat numerous 
human neurological conditions, including traumatic injuries and 
neurodegenerative diseases [100]. For ALS, the cell therapies up to now 
investigated include the transplantation of mesenchymal stem cells, which 
are derived from adipose tissue or bone marrow, human neural stem cells 
(NSCs), and glial restricted progenitor cells. 
As this thesis is focused on NSC transplantation, the stem cell-based 
approach for ALS treatment will be analyzed in detail in the next chapter. 
These strategies can be therapeutic through multiple mechanisms, which 
include not only cell replacement but also a reduction neuroinflammation, 
production of neurotrophic factors, and reduction of aggregates [101]. 
According to the website www.clinicaltrials.gov, there are currently 22 
ongoing clinical trials using transplantation of various stem cell types.       
The number of trials is elucidative of the rapid progress in the field with the 
prospective to finally find an effective treatment for this still incurable 
disease. 
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1.2 Stem Cells  
 
1.2.1 Induced Pluripotent Stem Cells (iPSCs) 
 
Stem cells are undifferentiated cells characterized by the ability to self-
renewal, giving rise indefinitely to more cells of the same cytotype by 
symmetric division, and to differentiate in mature cells through asymmetric 
division [102]. Thanks to their potential of differentiation, stem cells could 
be divided in totipotent, pluripotent and multipotent. Totipotent cells are 
able to differentiate in whatever kind of cells; they are in the first few cell 
divisions in embryonic development. After four days, the cells begin to 
specialize into pluripotent stem cells. Pluripotent cells are able to generate 
every cytotypes but they cannot give rise to an entire organism, they are in 
the inner cell mass of blastocystis. Multipotent cells are tissue specific and 
could differentiate in a limited number of cytotypes. 
Among stem cells, the most used in pre-clinical studies are pluripotent stem 
cells derived from embryos, known as embryonic stem cells (ESCs). 
The use of ESCs-differentiated cells, however, is complicated because of 
the problems of possible rejection if transplanted since they are 
heterologous, and because of ethical issues; in fact, the creation embryonic 
stem cells imply the destruction or manipulation of the pre-implantation 
stage embryos [103]. In order to overcome these obstacles, recently an 
important breakthrough has been made with the generation of stem cells 
derived from adult somatic cells. These cells are known as induced 
pluripotent stem cells (iPSCs) [104].   
The iPSCs are generated by reprogramming differentiated adult cells to a 
state of pluripotency, through the expression of transcription factors. 
iPSCs were first generated in 2006 from mouse fibroblasts [105], 
afterwards the iPSCs were generated from human cells in 2007 [106]. 
Introduction 
 
25 
 
To reprogram adult cells into iPSCs, Takahashi and Yamanaka used 4 
genes encoding key transcription factors with retroviral vectors.                  
In particular, skin fibroblasts were transfected with Sox2, Oct4, c-Myc and 
Klf4 [105, 106]. Currently, several studies improved the protocol for iPSC 
generation in terms of time and efficiency [104, 106-108]. The current 
methods for iPSC generation can be divided into three categories based on 
the vector types: virus (retrovirus, lentivirus, adenovirus, Sendai virus), 
DNA (plasmid, episomal plasmid, transposon) and cell-penetrating peptide. 
Because viral vectors have high efficacy of reprogramming, but present a 
major risk of tumor formation, many studies apply the non-viral method 
developed by Yu and colleagues in 2007 to generate iPSCs [104, 109-111]. 
They used a non-viral, non-integrating method for iPSCs generation 
through the transfection of 6 reprogramming factors vehiculated by 
episomal vectors. In particular, six reprogramming factors (OCT4, SOX2, 
NANOG, LIN28, c-Myc and Klf4) were conveyed through OriP/EBNA1 
carriers. This technique decreases the modifications in the recipient cells, 
making them more similar to physiological stem cells, and has a 
satisfactory efficiency [109]. 
The iPSCs show genetic and morphological features similar to the ESCs. 
Like ESCs, the iPSCs grow as colonies in adhesion and form spheres 
named embryoid bodies (EBs) when resuspended in low attached plates in 
appropriate medium. They also express the typical marker of pluripotency 
such as TRA1-60, TRA1-81, SSEA3, and SSEA4.  
The iPSCs maintain the potential of self-renewal and can differentiate into 
the three germ layers in vitro and in vivo, forming teratomas when 
transplanted in immunodeficient mice [112]. 
Since iPSCs are directly derived from adult tissues, they not only bypass 
the issue of the embryo manipulation, but they can be made in a patient-
matched manner [113]. 
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This means that each patient could have own iPSC line that can be used 
for autologous transplants without the risk of immune rejection.            
Moreover, the patient-specific iPSCs are an abundant and important source 
for the generation of specific cells directly involved in the pathology. 
For these reason, the iPSC technology is a promising tool, not only 
because it represents a rather novel source of autologous stem cells for the 
transplantation, but also to model human pathology in vitro (Fig. 4). 
 
 
 
Fig. 4 Potential applications for iPSCs. 
Generation of iPSCs is obtained by reprogramming adult somatic cells derived from biopsy 
of healthy or affected patients. Once generated, iPSCs are well suited to modeling human 
pathologies in vitro and screen drugs. Moreor, iPSCs are promising for regenerative 
medicine and can be used for autologous transplants. 
 
 
 
 
 
 
 
 
 
Introduction 
 
27 
 
1.2.2 iPSCs as an in vitro model of ALS 
 
Since ALS is an adult-onset disease characterized by high heterogeneity 
and few animal models exist, the iPSCs technology for ALS is particularly 
promising [114]. In fact, although animal models are useful and informative 
on the mechanisms behind ALS pathogenesis, their use requires months of 
studies, high costs and currently there are no models for some genetic 
mutations and sporadic forms of ALS. This leads researchers to focus on 
iPSCs technology to better understand the precise pathways causing MN 
death and to evaluate the effects of different drugs and therapies.  
Recently, iPSCs have been generated from patients carrying mutations 
associated to familial cases of ALS as well as from sporadic patients [115]. 
This technology represents a reliable model for ALS since the disease-
affected cells harbor the patients’ genomic backgrounds. 
Because patient-specific, the iPSCs can recapitulate in vitro the pathology, 
allowing us to understand the mechanisms of ALS and the 
differences/analogies among sporadic and familial forms of ALS and 
between different mutations. The iPSCs are particularly useful to model the 
ALS-related mutations that do not have a correspondent animal model such 
as C9orf72 and sporadic cases of ALS. The iPSCs can be derived from 
both fALS and sALS and are versatile in allowing investigators to 
differentiate these cells into multiple cell types, such as different types of 
specialized neurons as well as supporting glial cells [114]. This aspect is 
very important for ALS, where affected cells can be derived only post-
mortem from the CNS representing a scarce source of cells that reflect the 
end-stage momentum of the disease.  
The iPSCs can efficiently model in vitro ALS thanks to their ability to 
differentiate and generate the affected cytotypes.  
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They can differentiate using multi-step protocols in both upper and lower 
MNs and in surrounding astrocytes. 
To generate lower MNs from iPSCs, several protocols exist and all of them 
are based on knowledge of what happen in vivo. During embryogenesis, 
the neuroectodermal fate is determined by dual inhibition of bone 
morphogenic proteins (BMPs) and transforming growth factor beta (TGF) 
pathways that induce respectively mesoderm and endoderm fate.  
In vitro, neuralization of iPSCs is specified by inhibition of BMPs and TGF 
signaling by small molecules SB31542 and LDN193189. These molecules 
are added early during iPSC differentiation and they selectively block 
endodermal and mesodermal fate [116], determining the formation of 
NSCs. NSCs are multi-potent cells characterized by the capability to self-
renewal and to differentiate into neurons, astrocytes and oligodendrocytes 
[117]. To generate spinal MNs, which are positioned in the ventral horn of 
spinal cord, it is required the caudalization and ventralization of NSCs.            
For this reason, NSCs are treated with Retinoic acid (RA), which induces 
caudal neuronal subtypes of the hindbrain and rostral spinal cord and 
further directs neurogenesis, and Sonic Hedgehog (Shh), which determines 
dorsoventral spinal identity [118].  
The differentiation of iPSCs derived from ALS patient into lower MNs of the 
spinal cord was first reached by Dimos and colleagues in 2008 [119].       
They used skin fibroblasts derived from ALS patient with an autosomal 
dominant SOD1L144F mutation, which were reprogrammed to form iPSCs 
and then differentiate into lower MNs using a combination of Shh and RA. 
They showed a similar ability of these iPSCs to form MNs compared to 
ESCs. The efficiency of this protocol wasn’t high; in fact, they obtained less 
than 20% of MNs, as revealed by their expression for the marker Hb9. 
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Currently, several studies improved the protocol for MN generation in term 
of time and efficiency, based on combination of small molecules that 
accelerate their formation within 3 weeks [120].  
Although iPSC have the potential to differentiate in upper MNs, their 
generation in vitro is complex and more difficult compared to lower MN 
production. The existing protocols are not yet capable of generating specific 
classes of cortical neurons, including upper MNs [118]. One of attempts for 
upper MN generation consists in the conversion of iPSC into cortical 
progenitor cells in the absence of added morphogens and prolonged 
presence of the BMP inhibitor [121]. 
The iPSCs can also generate astrocytes in 90 days, resulting in cells with 
typical features of physiological astrocytes such as positive expression for 
GFAP, EEAT2 (excitatory amino acid transporter 2) and acquaporin 4 and 
able to secrete neurotrophic factors (BDNF, GDNF). Moreover, if co-
cultured with MNs, the iPSC-derived astrocytes enhance their survival and 
axon growth [122]. 
iPSC-derived cultures can mirror pathology observed in post-mortem 
patient neural tissues, indicating that this technique accurately represents 
cellular phenotype and that iPSCs are a useful tool for uncovering disease 
implications.  
Increasingly experiments are now performed using iPSC-derived MNs 
generated from ALS patients carrying mutations in SOD1, TDP-43, 
C9orf72, as well as sporadic ALS subjects (Table 3). 
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Table 3. iPSC-derived MNs from sALS and fALS patients.  
Mutation 
Phenotypes and 
mechanisms observed in 
iPSC-derived neurons 
Drug screening References 
SOD1D90A 
Neurofilaments aggregates 
and inclusions;               
Mutant SOD1 binds and 
destabilizes neurofilament 
mRNA 
TALEN-mediated 
homologous 
recombination 
[123] 
SOD1A4V 
(C9orf72?) 
Increased apoptosis;          
Reduced soma size;          
Shorter and fewer processes;   
Defects in mitochondrial 
morphology;                 
Unfolded protein response 
and ER stress 
Zinc finger nuclease 
(ZFN) correction of 
SOD1A4V mutation 
improves survival 
and soma size 
[124] 
SOD1G93A 
SOD1L144F 
Improved motor neuron 
survival by inhibition of 
GSK3α/β and Tak1-MKK4-
JNK-c-Jun 
Small molecules 
screening [125] 
SOD1A4V 
SOD1D90A 
SOD1G85S 
C9orf72 
FUSM511FS 
FUSH517Q 
Hyperexcitability blocked by 
Retigabine -   [126] 
TDP-43M337V 
Cellular vulnerability to PI3K 
inhibitors;                   
Increased detergent-insoluble 
TDP-43 proteins 
Specific siRNA 
reduces cytosolic 
TDP-43 
[127-129] 
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Mutation 
Phenotypes and 
mechanisms observed in 
iPSC-derived neurons 
Drug screening References 
TDP-43Q343R 
TDP-43M337V 
TDP-43G298S 
Reduced neurofilament 
expression;                 
Increased detergent-insoluble 
TDP-43;                   
Increased TNFα/NFκB 
signaling pathway and 
sensitivity to arsenite-induced 
cell death;                  
Increased RNA metabolism-
related genes 
Anacardic acid 
decreased TDP-43 
mRNA, reduced 
insoluble TDP-43 
and increased 
neurofilament 
expression 
[130] 
TDP-43A90V 
TDP-43M337V 
Cytoplasmic localization of 
TDP-43 protein;            
Reduced total TDP-43 
protein;                     
Decreased  miR-9 and 
precursor 
- [131] 
TDP-43M337V 
TDP-43G298S 
TDP-43A315T 
Axonal transport of target 
mRNAs 
- [132] 
C9orf72 
RNA foci and RAN translation 
products; Screening for RNA 
binding proteins that bind 
GGGGCC and characterize 
ADARB2;                   
Gene expression profiling;      
Increased glutamate 
cytotoxicity 
ASOs targeting 
C9orf72 rescued 
glutamate 
cytotoxicity and 
reversed disease-
specific 
transcriptional 
changes 
[44] 
C9orf72 
RNA foci detected but not 
RAN products; Support gain-
of-function properties in RNA 
foci to sequester RNA binding 
proteins and affect splicing 
and transcription;             
Gene expression profiling 
revealed enrichment in genes 
related to cell adhesion, 
synaptic transmission and 
reduced excitability upon 
depolarization 
ASOs targeting 
C9orf72 reversed 
disease-specific 
transcriptional 
changes 
[47] 
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Mutation 
Phenotypes and 
mechanisms observed in 
iPSC-derived neurons 
Drug screening References 
C9orf72 
RNA foci and RAN translation 
products;                   
Reduced cell viability in the 
presence of autophagy 
inhibitors 
- [45] 
C9orf72   
TDP-43M337V 
Initial hyperexcitability, 
followed by a progressive 
loss in action potential and 
synaptic activity 
- [133] 
C9orf72 
Decreased cell survival 
correlated with               
dysfunction in Ca2+ 
homeostasis;                
Reduced levels of the 
antiapoptotic Bcl-2; Increased 
endoplasmic reticulum stress;   
Reduced mitochondrial 
membrane potential;          
Abnormal protein 
aggregation;                
Stress granule formation 
- [134] 
C9orf72 
RanGAP physically interacts 
with RNA and is mislocalized;   
Nuclear import is impaired 
Small molecules and 
ASOs targeting the 
HRE G-
quadruplexes 
[135] 
FUSH517D 
Mis-localization of FUS;        
Stress granules              
Cellular vulnerability;          
Aberrant gene expression 
and/or splicing pattern 
- [136] 
Sporadic ALS 
Genetic analysis indicated 
association between 
mitochondrial function and 
cellular processes  
- [137] 
Sporadic ALS 
TDP-43 protein aggregates in 
iPSC-derived motor neurons 
from sporadic ALS cases 
High content 
screening for TDP-
43 aggregation 
inhibitors 
[138] 
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In particular, iPSC-MNs with SOD1 mutations showed a high propensity to 
die via apoptosis, reduction in term of soma size and in number of neuronal 
processes, which are also shorter compared to healthy MNs. Moreover, 
genome wide analyses revealed altered expression in genes implicated in 
cytoskeleton organization, mitochondrial function and structure and 
unfolded protein response. More recently, researchers found in iPSC-MNs 
possessing SOD1 mutations the presence of neurofilament aggregation 
and neurite degeneration [123]. 
iPSC-derived MNs carrying TARDBP mutations have showed increased 
levels of soluble and detergent-resistant TDP-43 and reduced survival. 
Gene expression profiling in iPSC-derived MNs revealed misregulation of 
genes linked to RNA metabolism and cytoskeleton functions [130].  
Similar to those reported in SOD1 MNs, iPSC-derived MNs with TDP-43 
mutation showed a significantly reduction in neurofilament expression. 
Motor neurons derived from differentiation of iPSCs with C9orf72 repeat 
expansion well recapitulated some of the neuropathological hallmarks 
observed in ALS patients. Several groups showed the co-localization of 
repeat mRNA with RNA binding proteins, which form intranuclear RNA foci, 
altered gene expression patterns and RAN translation products in iPSC-
derived MNs [44, 47, 139]. Also, C9orf72 iPSC-derived neurons provided a 
convenient tool to investigate the potential loss-of-function effect of C9orf72 
gene product in the regulation of endosomal trafficking and in the 
pathogenesis of TDP-43 proteinopathy [140, 141]. Moreover, iPSC-
neuronal cultures from C9orf72 patients have contributed to identification of 
nuclear RNA export defects [142] and nuclear import impairment caused by 
nucleocytoplasmic transport protein mislocalization [135]. 
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An important benefit of iPSC cultures consists in the opportunity to model 
disease when the genetic causes are unknown, such as in sporadic ALS 
forms. In 2013, Burkhardt and colleagues identified intranuclear TDP-43 
aggregates in different lines of iPSC-derived MNs from sALS patients 
without mutations in genes already known to be linked in ALS TDP-43 
proteinopathy [138].  
Finally, iPSCs provide a platform for the investigation of therapeutics; the 
screening of new compounds in iPSC derived from ALS patients can be 
useful to find an effective cure. For example, to correct SOD1A4V/+ 
mutation, researchers used gene targeting approach mediated by zinc 
finger nuclease (ZFN) which showed significant rescues in both survival 
and soma size in corrected MNs [124]. Similar approach (mediated by 
TALEN-based homologous recombination) was used to correct the 
SOD1D90A mutation [143]. 
Drug screening assays performed on TDP-43 iPSC-derived MNs led 
researchers to identify a histone acetyltransferase inhibitor (anacardic acid) 
as a potential treatment for ALS. In fact, treatment with anacardic acid 
determined a reduction of the insoluble TDP-43 resulting in an 
enhancement in neurite length and in expression of neurofilaments. 
Anacardic acid also down-regulated the RNA metabolism-related genes 
and reversed the changes in apoptotic pathway [130]. 
Two studies revealed that the treatment with antisense oligonucleotide 
(ASOs), that targets the GGGGCC repeat, mitigated C9orf72 disease 
characteristics in iPSC derived cultures [44]. 
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Challenges  
Challenges with iPSC technology are various. First of all, the efficiency of 
iPSC reprogramming is often low, less than 0.02% in fibroblasts [106] 
costing time and resources.  
Another important aspect to be considered for basic and translational 
studies is the possibility to create iPSCs free from exogenous sequences 
and from genes involved in the reprogramming process. This is now 
possible thanks to the use of episomal vectors and the Sendai virus, which 
remain episomal and not integrating into the host genome [144]. However, 
the transfection efficiency is reduced due to antiviral response of cells. 
During or after reprogramming, chromosomal abnormalities can occur, 
causing potential effects on the cellular phenotypes [145]. For this reason, 
karyotype analysis of iPSCs is considered a standard for ensuring that 
findings are linked to ALS and not as a result of chromosomal alterations. 
Moreover, the comparison of results from lab to lab can be challenging due 
to the multiplicity of differentiation protocols. The standards to define iPSC-
derived MNs or astrocytes consist on the identification of a small subset of 
specific markers, such as Hb9 and GFAP respectively. In addition, the 
purity of cultures derived from iPSC is always of concern. In fact, population 
studied can be heterogeneous determining non-cell autonomous effects 
that influence the experimental results [114]. 
Finally, since cultures generated from iPSC do not reach fully mature 
phenotypes, a relevant concern is whether iPSC derived MNs adequately 
model late onset diseases, like ALS, making it challenging to study adult 
late-onset neurodegeneration. To bypass this issue, an age mimicking 
gene (progerin) was introduced in cells in order to accelerate the aging 
process [99]. Despite the necessity to improve the reprogramming process, 
this technology remains an important tool to model ALS, contributing to an 
increasingly robust research system [146]. 
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1.2.3 Stem cell transplantation as therapy for ALS  
 
Given the multifaceted nature of ALS, the therapy based on transplantation 
of differentiated cells from ESCs and iPSCs has recently become an 
attractive option. Since many pathological mechanisms appear to 
contribute in ALS onset, the therapeutic strategies that targeted only one 
mechanism may have minimal impact on disease phenotype [147].              
On the contrary, approaches that affect many pathophysiological 
mechanisms at the same time could lead to a therapeutic synergy. 
Among strategies that can be therapeutic through multiple mechanisms 
there is the transplantation of stem cells. In fact, although the initially 
proposed mechanism was cell replacement, now it is clear that stem cells 
may also provide a large number of benefits by modulating the micro-
environment, leading to a reduction of inflammation and protecting MNs 
and neuronal circuitry [148]. 
Thanks to the ability of stem cells to differentiate in neuronal subtypes lost 
in ALS, transplanted stem cells-derived neurons can restore MN function 
through cell replacement.  
After transplantation into animal models with MN injury, stem cell-derived 
MNs are able to extend axons and form NMJs with host muscles, giving 
rise to a partial recovery from paralysis [149-152].  
Despite the success of stem cell-based approaches in ALS animal models 
[153], some issues of direct MN replacement limit the clinical translation in 
human. In fact, in order to functionally replace degenerating MNs, the 
engrafted stem cell-derived neurons must receive functional synapses and 
send axons over long distances to the target muscles and form NMJs. Due 
to these limitations, the direct replacement of MN populations seems 
unlikely to be a viable treatment option in the short term for ALS.  
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Therefore, it is evident that the mainly beneficial effect derived from 
transplantation of stem cells consists in modulation of the micro-
environment rather than cell replacement [154]. 
Stem cells transplantation determines environmental enrichment, 
counteracting MN loss, by releasing neurotrophic factors, eliminating toxic 
factors, reducing inflammation and generating auxiliary neural networks 
around affected areas. These effects determine a more realistic near-term 
clinical goal for ALS. 
Among the trophic factors produced by stem cells, glial-derived 
neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), 
insulin-like growth factor-I (IGF-I), and vascular endothelial growth factor 
(VEGF) protect and support neurons from degeneration [155].  
To enrich and modulate neural micro-environment, many strategies use 
stem cells to furnish de novo synthesized neurotrophins and to delivery 
them to the foci of disease [156]. It is also possible to manipulate stem cells 
in order to make them able to produce trophic factors. 
Over the last decade, many preclinical studies have been conducted with 
the aim to test the therapeutic effects of stem cells transplantation, using 
various types of stem cells and different routes of administration (Table 4). 
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Table 4. Stem cell transplantation in preclinical studies  
Type of Stem 
Cells Animal model 
Additional 
treatment Results Reference 
Human embryonic    
germ cells  
Rats with motor 
neuron injury 
induced by 
sindbis virus 
- 
Blood brain 
barrier  
improvement,     
Limb strength 
[157] 
Mouse embryonic 
stem cells  
Rats with motor 
neuron injury 
induced by 
sindbis virus 
RA and Shh 
agonist - [150] 
Human neural       
precursor cells  
Mutant SOD rats 
GDNF,       
Gene 
transfer 
Blood brain 
barrier  
improvement 
[158] 
Human neural       
precursor cells  
Mutant SOD rats - 
Blood brain 
barrier  
improvement,    
Extended 
survival 
[159] 
Mouse neural stem 
cells LeX+CXCR4+   Mutant SOD mice - 
Rotarod,         
Extended 
survival 
[160] 
Human immortalized 
neural stem cells  
Mutant SOD mice 
VEGF,       
Gene 
transfer 
Rotarod,         
Extended 
survival 
[161] 
Rat neural stem 
cells  Mutant SOD rats 
GFP 
labeled - [162] 
Mouse progenitor 
stem cell c-kit+       Mutant SOD mice 
GFP 
labeled 
Rotarod,         
Extended 
survival 
[163] 
Human neural stem 
cells   
Mutant SOD mice 
Olig2 gene 
transfer,      
Shh 
treatment 
Rotarod,         
Extended 
survival,         
Limb placement 
[164] 
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NSCs in pre-clinical studies  
Before stem cell therapy can move to the clinic as a treatment for ALS, 
some aspects have to be considered. In fact, the proper type of stem cells 
and their delivery must be carefully considered [148]. 
Compared to other types of stem cell, NSCs are particularly promising for 
ALS treatment. This is due to the capability of NSCs to primarily 
differentiate into neuronal and glial cells, determining a life-long source of 
nervous cells. Moreover, since more differentiated than pluripotent stem 
cells, NSCs reduce the risk of forming teratoma after transplantation. 
Different preclinical studies have demonstrated the positive effects of their 
transplantation in vitro and in ALS animal models [110, 165].  
Teng and colleagues have demonstrated that NSCs derived from 
embryonic stem cells (mouse and human) transplanted into the spinal 
cords of SOD1G93A adult mice effectively improved neuromuscular 
performance and respiratory function, slowing ALS progression and 
prolonging survival. Moreover, in 25% of affected mice treated with NSCs, 
the ALS phenotype seemed completely rescued [165].  
Given the ability to overcome ethical issues of the embryo manipulation, 
human iPSCs provide an alternative source of NSCs. Recently, our 
laboratory has demonstrated the beneficial effects of a specific 
subpopulation of iPSC-derived NSCs selected for their aldehyde 
dehydrogenase (ALDH) activity and VLA4+ positivity. This subpopulation of 
NSCs has been selected in order to enhance their pluripotency and 
migration capability. Since ALDH is a marker of pluri/multipotency, NSCs 
selected for this marker increase their growth/differentiative potential and 
ability to replace cells. The presence of VLA4 integrin in NSCs allows them 
to cross the blood-brain barrier (BBB), particularly in the presence of 
inflammation as in ALS.  
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When intrathecally transplanted into the SOD1G93A mice, these cells 
migrate into the spinal cord, improving motor performance and increasing 
life span [110]. 
Overall, preclinical studies provide promising data and could pave the way 
for clinical trials in humans. However, more work is necessary in order to 
acquire additional information about the details of stem cell-based therapy 
effects. 
 
 
Ongoing clinical trials of NSC transplantation 
On the basis of the positive results of NSC transplantation obtained in 
preclinical studies, the US FDA approved a “Phase I, Open-label, First in 
Human, Feasibility and Safety Study of Human Spinal Cord Derived Neural 
Stem Cell Transplantation for the Treatment of Amyotrophic Lateral 
Sclerosis” (NCT01348451). This trial, which is coordinated by Dr. Glass at 
Emory University, utilized an approach of “risk escalation” in terms of ALS 
severity, site and number of injection and number of transplanted NSCs. 
The trial design consists in 5 groups which represent both different 
inclusion criteria and location of surgery (Table 5). 
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Table 5. Design of Phase I trial of human NSC transplantation for ALS 
Group N° patients N° of injections Target N° of NSCs 
A1 3 5 total, 5 unilateral Lumbar cord 5 x 105 
A2 3 10 total, 5 per side Lumbar cord 1 x 106 
B 3 5 total, 5 unilateral Lumbar cord 5 x 105 
D 3 5 total, 5 unilateral Cervical cord 5 x 105 
C/E 3 
15 total, 5 per side 
lumbar         
 
5 unilateral cervical after 
observation period 
Lumbar cord 
 
Cervical cord after 
observation period 
 
1 x 106          
 
5 x 105 
 
 
 
To ensure survival of the transplanted NSCs, patients were subjected to a 
multi-drug regimen that includes intravenous injections of basiliximab and 
methylprednisolone during the first week, as well as mycophenolate mofetil 
and tacrolimus for 6 months. 
The treatment was apparently safe. In fact, no tumor formation was evident 
in any subject; moreover, NSCs engrafted the host tissue, as confirmed by 
the presence of living cells in the injection regions. Adverse events were 
mostly related to the immunosuppression regimen.  
So far, 7 patients enrolled in phase I trial are dead and the autopsy 
analyses on spinal cord tissues of 7 patients that died revealed the 
presence of engrafted donor cells. 
Despite the purpose of phase I is not to evaluate the efficacy, the disease 
progression appeared to be reduced after surgical transplantation, in 
particular in group C/E. 
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Clinical evaluations such as ALS Functional Rating Scale-Revised 
(ALSFRS-R), quality of life and forced vital capacity exhibited no 
acceleration of disease; moreover, in most of the cases, hand-held 
dynamometry (HHD), grip strength testing (GST) and electrical impedance 
myography outcomes were improved.  
Given these results, the FDA approved the “Phase II, Open-label, Dose 
Escalation and Safety Study of Human Spinal Cord Derived Neural Stem 
Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis” 
(NCT01730716, clinicaltrials.gov). This phase aims to assess the maximum 
tolerated dose of NSCs, treating groups with an increasing dose of NSCs 
via intraspinal cord injections and measuring the same clinical aspects as 
the phase I trial (Table 6). 
Since results of phase I/IIa trials are promising [166], the phase IIb/III trial is 
planned.  
 
Table 6. Design of Phase II trial of human NSC transplantation for ALS 
Group N° patients N° of injections Target N° of NSCs 
A 3 10 total, 5 per side Cervical cord 2 x 106 
B 3 20 total, 10 per side Cervical cord 4 x 106 
C 3 20 total, 10 per side Cervical cord 6 x 106 
D 3 20 total, 10 per side Cervical cord 8 x 106 
E 3 20 total, 10 per side for each target 
Cervical cord,         
followed by lumbar cord 16 x 10
6 
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The first Italian clinical trial using NSCs for ALS started in 2010.                 
Named "Intramedullary transplantation of human neural stem cells as a 
putative therapy for ALS: Proposal for a Phase I clinical trial", this study 
was coordinated by Dr. Vescovi at the Azienda Ospedaliera Santa Maria 
(Terni). Six non-ambulatory patients were treated with injections into the 
lumbar spinal cord; three of them received unilateral injections, while the 
remaining ones received bilateral injections. From the point of view of 
clinical follow-up patients did not manifested complications related to the 
experimental procedure [167].  
Given the promising results obtained in both preclinical and phase I/IIa 
trials, NSC-based approach represents a potential promising tool compared 
with other pharmacological and molecular treatments in MN disease field.
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2. AIMS OF THE STUDY 
 
ALS is a neuromuscular disorder characterized by the progressive 
degeneration of upper and lower MNs that leads to a muscular paralysis 
and death within 3-5 years from the onset due to respiratory failure. 
Up to now, there is no effective cure for ALS beyond palliative care and 
Riluzole, which delays disease progression (2-3 months) without a 
significant impact on the prognosis. 
Stem cell transplantation is a promising therapeutic tool thanks to its 
multiple effects; in fact, stem cells can protect endogenous MNs through 
the production of neurotrophic factors, the reduction of neuroinflammation 
and eventually the replacement of degenerating cells. 
The aim of this study consists in the selection of a subpopulation of NSCs 
able to engraft and migrate through the nervous system parenchyma, to 
replace and protect degenerating MNs and to improve ALS phenotype. 
 
In detail, the specific aims of this study are:  
- Differentiation of iPSCs, derived from the reprogramming of skin 
fibroblasts of control subjects, into NSCs. This cell source is 
attractive due to its availability, pluripotency similar to ESCs, and no 
ethical controversy. 
 
- Selection of a specific subpopulation of NSCs able to engraft and 
migrate through the nervous system. We selected NSCs for three 
markers: Lewis X (LeX), a glycoprotein involved in adhesion and 
migration of stem cells in the pre-implantation embryo; CXCR4, a 
chemokine receptor that increases the sensitivity of the cells to be 
recruited by the host spinal cord; and β1 integrin, a subunit of VLA4 
receptor that allows cells to cross the blood-brain barrier.  
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- Injection of LeX+CXCR4+β1 NSCs in an ALS mouse model        
(the SOD1G93A mouse) and evaluation of their ability to engraft the 
central nervous system.  
 
- Testing and monitoring the motor functions and survival of treated 
mice in order to determinate the effects of cell therapy.  
 
- Analyzing any eventual changes in ALS features such as MN and 
axon number, NMJ preservation and neuroinflammation. 
 
- Evaluation of the NSC effects in a human in vitro model of ALS 
(iPSC-patient specific).  
 
- Investigation of potential molecular mechanisms linked to the NSC 
therapeutic effect. More specifically, we will observe whether the 
production of neurotrophic factors, the inhibition of pathological 
astrocytes activities and the modulation of GSK3β pathway can be 
related to the NSC protective effect on ALS phenotype. 
 
 
Overall, this study aims to contribute to set the stage for clinical trials based 
on NSC transplantation for the effective treatment of ALS and can provide 
novel insight into the mechanisms underlying this approach. 
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3. MATERIAL AND METHODS  
 
3.1 Generation of iPSCs and differentiation in NSCs 
To generate iPSCs, we reprogrammed human fibroblasts obtained from 
skin biopsy of a control subject. The reprogramming was carried out by 
nucleofection of three oriP/EBNA1-based episomal vectors encoding for the 
human genes OCT4, SOX2, c-MYC, NANOG, KLF4, and LIN28 [104, 109-
111]. After electroporation, fibroblasts (1.0 × 106 cells per nucleofection) 
were seeded onto 3 × 10–cm dishes covered with Matrigel (BD Biosciences) 
in fibroblast culture medium, which was changed every other day.             
At day 4, we replaced fibroblast culture medium with human stem cells 
medium (E8, Life Technology). After 3 weeks, it was possible to identify first 
iPSC colonies with stem cells morphology. We picked colonies that were 
morphologically similar to ES cells to further analyze and expand them. 
Then iPSCs were differentiated into NSCs using a multistep protocol of 10 
days [110]. On day 0 of neural differentiation, the iPSC colonies were 
detached and put in suspension in order to form EBs in human stem cells 
medium for four days. Then the medium was switched to the neural 
differentiation medium (composed by DMEM/F12, N2 supplement, Neaa, 
and 1 mg/ml heparin). On day 7, the iPSC aggregates were collected and 
transferred into a 60-mm Petri dish in neural differentiation medium.             
At day 10, we obtained a neuroectodermal lineage of NSCs.  
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3.2 Isolation of the LeX+CXCR4+β1 NSC subpopulation 
After differentiation of iPSCs into NSCs, we selected NSCs for three 
markers. First of all, we enriched the population of CXCR4 positive cells 
using a magnetic cell separation strategy based on the CXCR4 MicroBead 
Kit (Miltenyi Biotech), following the manufacturer's instructions. Further, we 
evaluated the percentage of CXCR4+ NSCs with FACS. In order to 
distinguish dead cells, 10 millions cells/tube were incubated with 5 µl of 
AAD (Becton Dickinson Biosciences, BD) and with CXCR4-APC (mouse, 
1:10, Miltenyi) for 10 minutes at 4°C, according to manufacturer’s 
instructions. The CXCR4+ NSC subpopulation was re-seeded and 
expanded in the same neural medium. Then, the cells were sorted for their 
expression of integrin β1 (CD29-PE, mouse 1:50, Miltenyi) by FACS. The 
subset of NSCs CXCR4+β1+ were plated and expanded. The final 
population was further selected by FACS for their positivity for Lewis X, 
CXCR4 and β1 (antibodies and condition above described plus the LeX-
FITC mouse, 1:10, Miltenyi). As negative control, we used the same 
isotypic Ig antibody. Flow cytometric sorting was performed using FACS 
Vantage Aria (BD Biosciences) [110]. For cell expansion and 
characterization, LeX+CXCR4+β1+ NSCs were growth in neuronal medium 
containing FGF-2 [110].  
 
 
3.3 Immunocytochemistry of iPSCs and their derivates  
The staining protocol for iPSCs and their derivates consisted in fixation with  
4% paraformaldehyde (PFA) for 10 minutes, permeabilization with 0.25% 
Triton X-100 and blocking for 1 hour at room temperature with 10% BSA 
and 0.3% Triton X-100 in 1× PBS. 
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We incubated the cells with primary antibodies overnight at 4°C and with 
secondary antibodies for 1.5 h at room temperature (Alexa Fluor 488 or 
594-conjugated anti-mouse, rabbit or goat, 1:400, Life Technologies).      
We used the following primary antibodies: SSEA-3 (mouse, 1:100, 
Chemicon), SSEA-4 (mouse, 1:500, Chemicon), TRA1-60 (mouse, 1:500, 
Chemicon), TRA1-81 (mouse, 1:500, Chemicon), LeX (CD15-FITC BD, 
according to manufacturer’s instructions), CXCR4-APC and PE (Miltenyi, 
according to manufacturer’s instructions), CD29-PE (mouse, 1:50,Miltenyi), 
Pax6 (mouse, 1:100, Thermo fisher), Nestin (rabbit, 1:200, Millipore), SOX2 
(mouse 1:1000, Millipore), TuJ1 (rabbit, 1:300, Millipore), GFAP (rabbit, 
1:300, Sigma), SMI-32 (mouse, 1:100, Millipore), Hb9 (rabbit, 1:200, 
Millipore), ChAT (goat, 1:125, Millipore), MAP2 (mouse, 1:100, Sigma), O4 
(mouse, 1:200, Millipore). Acquisition of images was realized using the 
confocal LEICA LCS2 microscope. 
 
 
3.4 Animal models 
For our in vivo experiments, we employed transgenic mice of the strain 
B6.Cg-Tg(SOD1-G93A)1Gur/J which carries a high copy number of the 
mutant human SOD1 gene containing the Gly93Ala (G93A) mutation in the 
genome. Transgenic mice were imported by Jackson Laboratory and all 
experiments performed with animals were approved by the University of 
Milan and Italian Ministry of Health, and are in compliance with US National 
Institutes of Health Guidelines.  
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3.5 Genotyping  
Progeny was obtained by breeding SOD1G93A males with C57BL/6 WT 
female mice. All newborn mice were genotyped using polymerase chain 
reaction (PCR). Genomic DNA was obtained from excision of a few 
millimeters from the end of a mouse's tail. To extract DNA, tails were 
soaked at 55°C overnight in TNES buffer and proteinase K. To precipitate 
DNA, NaCl and ethanol were added. The DNA was resuspended in TE 
buffer and amplified by PCR. SOD1 gene was amplified by the Expand 
Long Template PCR System (Roche Diagnostics GmbH, Mannhein, 
Germany) with the forward primer 5’- CAT CAG CCC TAA TCC ATC TGA-
3’ and the reverse primer 5’-CGC GAC TAA CAA TCA AAG TGA-3’. An 
internal positive control was amplified with forward primer 5’-CTA GGC 
CAC AGA ATT GAA AGA TCT-3’ and reverse primer 5’-GTA GGT GGA 
AAT TCT AGC ATC ATC C-3’. 
 
 
3.6 Transplantation of LeX+CXCR4+ β1 NSCs 
Before transplantation, donor NSCs were genetically engineered in order to 
express the GFP reporter [109]. Cells (1 x 106) or vehicle only (saline 
solution) were administered into 90 days old SOD1G93A mice by 
intrathecal injection (5 µl). Infusions were performed between L1-L2 regions 
of the spinal cord using an apposite syringe (Hamilton, 30 gauge). 
Treatment has no collateral effects. Experimental groups consist in 12 mice 
(6 males) treated with NSCs and 15 mice (8 males) vehicle-treated.      
After treatment, all groups of mice were daily monitored up to the end stage 
for clinical signs of ALS, survival and histological evaluation of donor cell 
phenotype by blind examiners. For the entire length of the experiments, all 
animals received the immune suppressor FK506 intraperitoneally (1.0 
mg/kg).  
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Littermates were equally distributed among the NSC- and vehicle-treated 
group and the gender was balanced. To perform histological analyses and 
quantification of MNs and axons, we used another group of animals at end 
stage (n= 6 mice per condition) [110]. 
 
 
3.7 Tissue analysis 
At the end stage of the disease, animals were euthanized and tissues were 
collected for histopathological analysis. Tissues were fixed for 24 hours in 
4% PFA, and soaked in 10% sucrose solution in PBS 1X (pH 7.4) 
overnight. Then tissues were frozen in isopentane cooled with liquid 
nitrogen and cryosectioned. Every tenth sections (20 µm) was collected, 
mounted on gelatinized glass slides and analyzed.  
For immunostaining, all sections were blocked for 1 hour at room 
temperature with 10% BSA in 1× PBS and 0.3% Triton X-100. 
In order to analyze the acquired phenotype of GFP+ transplanted NSCs, 
spinal cord sections were stained overnight at 4°C with primary antibodies: 
NeuN (mouse, 1:200, Chemicon), TuJ1 (mouse, 1:200, Chemicon), ChAT 
(rabbit, 1:100, Chemicon), SMI-32 (mouse, 1:100, Millipore), Nestin 
(mouse, 1:200, Millipore), O4 (mouse, 1:200, Chemicon) and GFAP 
(mouse, 1:200, Sigma). After three washes to remove primary antibodies, 
appropriate secondary antibodies were added (mouse and rabbit) 
conjugated with FITC, CY3, RPE or biotin (1:200, Jackson 
ImmunoResearch Laboratories, Inc., and Dako) for 1h at room 
temperature. 
To detect GFP expression, an anti-GFP antibody rabbit serum Alexa 488 
conjugated (1:400, Molecular Probes) was used.  
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The co-localization of GFP signal and cell-specific markers was evaluated 
by fluorescence microscopy (Zeiss Axiophot) and confirmed by laser 
confocal scanning microscopy (Leica TCS SP2 AOBS). For an unbiased 
stereological quantification of cells GFP positive, optical dissectors and 
random sampling were employed. For this purpose, we considered every 
tenth coronal sections (20 µm) throughout the entire spinal cord (25 
sections per animal).  
Cell density evaluation was carried out using the optical dissector protocol. 
Optical dissectors (100 × 70 × 14 µm) were randomly selected and the 
number of positive cells in each dissector was defined. The total number of 
transplanted cells divided by the total volume of optical dissectors 
determined the cell density. 
The volume of tissue per specimen (Vcord) was established by means of 
the Cavalieri method and, multiplied by the number of donor cells per mm3 
(Nv), resulted in the total number of donor cells per specimen (n = Nv × 
Vcord) [110]. 
 
 
3.8 Evaluation of neuromuscular function and survival 
After transplantation, all mice were daily monitored for the typical hallmarks 
of ALS. All functional analyses were performed by blinded investigators. 
Neuromuscular function was determined using an inverted grid hanging test 
[168]. In this test, mice were placed onto a grid that was gently inverted. 
The latency to fall was recorded up to 60 seconds. Mortality was scored as 
the age at death. Animals were sacrificed if were unable of righting 
themselves within 30s when positioned on their back [110]. 
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3.9 Neuropathological analysis of MNs, axons and NMJs 
To determine the number of MNs, paraffin serial sections (12.5 µm) of 
lumbar spinal cord were Nissl-stained using methylene blue and analyzed 
using the optical microscope. 
For axon counting, spinal cord was soaked in 2.5% glutaraldehyde 
overnight and post-fixed in 2% osmium tetroxide. Samples were then 
dehydrated in ethanol and embedded in Epon resin. Toluidine blue staining 
was performed on semi-thin transverse sections of L4 roots and then 
examined with light microscopy [110]. 
The NMJ evaluation was performed on the tibialis anterior (TA) muscle of 
each mouse. The staining was performed using α-bungarotoxin-555 
conjugated (1:500, Life Technologies) and the 2H3 antibody (neurofilament 
clone 2H3, mouse, 1:100, Developmental Studies Hybridoma Bank) 
Muscles were dissected and immunohistochemically processed as 
described above. Across muscles, we identified a minimum of 50 α-
bungarotoxin positive motor end plates and evaluated for overlapping 2H3 
positive MN terminal. The 2H3 neurofilaments determine the type of NMJ, 
which could be categorized in: distinct, when the staining of 2H3 is bright, 
defined and overlying the endplate; diffuse, if the staining is undefined or 
partially overlying the endplate; devoid, when there is no 2H3 signal or no 
overlying the endplate. 
 
 
 
 
 
 
 
 
Material and Methods 
 
53 
 
3.10 Macro- and micro- gliosis evaluations  
Microglial cells and astrocytes quantification was achieved by 
immunohistochemistry. Sections of the lumbar spinal cord for each mice in 
each group were processed as described above and stained with primary 
antibodies: GFAP (mouse, 1:200, Sigma), s100β (rabbit, 1:3000, Abcam) 
and Iba1 (rabbit, 1:500, Wako). 
 
 
3.11 Analysis of GSK3β activity 
In vitro, the GSK3β activity was evaluated by immunocytochemistry using 
an anti-P-GSK3β (rabbit, 1:100, Cell Signaling) in iPSC-derived MNs [169]. 
For the in vivo analyses, level of GSK3β protein was quantified by western 
blot in spinal cord of WT and affected mice. 
Frozen spinal cord specimen were homogenized in RIPA-buffer (50 mMTris 
pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate and 0.1% 
SDS) supplemented with protease inhibitor cocktail tablets (Roche). The 
protein content was measured using Lowry assay. An amount of 30 µg of 
total protein was boiled in Laemmli buffer for 5 min and separated on an 
8% sodium dodecyl sul-fate–polyacrylamide gel electrophoresis SDS–
PAGE. After electrophoresis, proteins were transferred on a nitrocellulose 
membrane, blocked in 5% BSA (for 1 hour at room temperature) and 
incubated at 4°C overnight with primary antibodies. The following 
antibodies were used: GSK3β (rabbit, 1:2500, Abcam), Akt (rabbit, 1:1000, 
Sigma), β-catenin (mouse, 1:500, Santa-Cruz), actin (rabbit, 1:1000, 
Sigma). The day after, the membranes were incubated with appropriate 
secondary peroxidase-conjugated antibody (Dako, diluted 1:2700), and 
signals were detected with an ECL detection kit (Amersham, GE 
Healthcare). 
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3.12 Differentiation of human iPSCs into spinal MNs 
We applied a multistep differentiation protocol to promote formation of 
spinal MN phenotype starting from iPSCs [109]. First, iPSCs were 
differentiated in NSCs using the 10 day protocol described above 
(DMEM/F12, Neaa, N2 and heparin). Then we added retinoic acid (0.1 µM; 
Sigma-Aldrich) to induce neural caudalization. To promote ventralization, 
we added Sonic hedgehog (100-200 ng/ml; R&D Systems) at day 17.           
For MNs maturation, BDNF (brain-derived neurotrophic factor) and GDNF 
(glial cell-derived neurotrophic factor) (10 ng/ml; PeproTech) were added at 
day 24. To enrich the MN population, a centrifugation gradient protocol was 
used [170]. Cells were fixed after at least 24 hours post plating and stained 
for the neuronal and MN markers like SMI-32 (mouse, 1:100, Millipore), 
Islet1/2 (rabbit, 1:200, Millipore), Hb9 (rabbit, 1:200, Millipore), ChAT (Goat, 
1:125, Millipore), MAP2 (mouse, 1:100, Sigma). MNs were also transduced 
with lenti-Hb9::GFP [170]. 
 
 
3.13 Co-culture of MNs and SOD1G93A astrocytes  
Murine astrocytes and iPSC-derived MNs were plated in a transwell co-
culture assay. In this assay, the porous membrane separates the two 
compartments allowing only the diffusion of soluble components. 
On the bottom chamber of the co-culture, iPSCs-MNs were seeded. 
Astrocytes were obtained either from newborn spinal cords of SOD1G93A 
and WT mice [170-172] and were grown in glial medium: DMEM (Life 
Technologies) supplemented with 10% fetal bovine serum (Life 
Technologies) and 1% of penicillin/streptomycin (Life Technologies). 
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To remove any remaining microglial cells, 2-week-old flasks were 
maintained in agitation (200 rpm for 6 h) and astrocytes were detached by 
0.25% trypsin (Life Technologies) and reseeded at a density of 20.000 cells 
per cm. To evaluate their neuroprotection ability, NSCs were plated in the 
upper compartment 48 hours after induction of astrocyte toxicity.                 
Co-cultures were maintained for an additional 3 weeks. To identify MN 
cells, the Hb9::GFP gene reporter was used [170]. iPSC-derived MNs were 
also stained for: Islet1/2, Hb9, ChAt, MAP2 and Smi-32 (antibody’s 
information described above) and P-GSK3β (rabbit, 1:100, Cell Signaling). 
In order to evaluate the survival of MNs, cell counting was performed using  
10 randomly selected fields per well (three wells/condition/experiment in 
four to five experiments).  
 
 
3.14 Enzyme-linked immunosorbent assay  
Secretion of BDNF, GDNF, NT3 and TGF-α by NSCs was measured in 
duplicate by ELISA (R&D Systems, Minneapolis, USA) according to the 
manufacturer’s instructions. Brefly, fresh neural medium was added to NSC 
culture and, 24 hours later, it was collected for the ELISA test. Neural 
medium was centrifuged and 50 µl of supernatant were added to an ELISA 
microplate pre-coated with monoclonal antibodies specific for human 
BDNF, GDNF, NT3 or TGF-α. After 2 hours of incubation, specific enzyme-
linked polyclonal antibodies were added to each well and incubated for 2 
hours. A substrate solution was added and color develops in proportion to 
the amount of cytokines bound in the initial step. The stop solution was 
used to block color development. The color intensity was read at 450 nm 
within 30 minutes. The standard curve showed a direct correlation between 
optical density and neurotrophin concentration. 
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3.15 Analysis of TRPV1 expression and cytotoxicity assay  
Conditioned medium experiments and cytotoxicity assay were performed to 
analyze the transient receptor potential vanilloid subfamily member-1 
(TRPV1) on astrocytes. Astrocytes were stained with GFAP (green) and 
TRPV1 (red). Cells were plated on μ-slide 8-well plates coated with poly-L-
lysine (PLL) and treated with NPC-conditioned medium with or without 
TRPV1 antagonist. As positive control, the ER stress inducer thapsigargin 
(30 ng/ml) was added. For live-cell ER labelling, ER tracker solution (500 
nM) was added to the cells for 30 min at 37 °C. Subsequently, cells were 
fixed with 4% PFA for 15 min at room temperature. After incubation with 
NPC-conditioned medium, the relative increase in ER size was quantified 
by confocal microscopy. As control, non-conditioned media was used and 
incubation with thapsigargin was set as 100%. For antagonist treatment, 
the cells were pre-incubated with antagonists for 3 h in control medium. 
Afterward, the medium was changed with medium containing agonist and 
antagonist. CytoTox-Fluor Cytotoxicity Assays (Promega) were measured 
(485 nm/520 nm) with the fluorometer. 
 
 
3.16 Statistical analysis 
For statistical analyses, we used StatsDirect for Windows (version 2.6.4).In 
all analyses, the null hypothesis was rejected when the p-values were less 
than 0.05. In culture assays, differences between means were analyzed 
using the two-tailed Student's t-test. ELISA was evaluated by Student's t-
tests. The in vitro and in vivo neuropathological parameters were analyzed 
by one-way ANOVA followed by a Tukey post hoc analysis. For survival 
comparison, Kaplan–Meier survival curve and the log-rank test were used. 
The functional results were analyzed by an ANOVA two way test for 
multiple comparisons.  
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4. RESULTS  
 
4.1 Generation of iPSCs and their differentiation into NSCs 
For our in vitro and in vivo experiments, we used NSCs derived from 
human differentiated iPSCs. We generated an iPSC line reprogramming 
fibroblasts obtained from skin biopsies of a control subject (Fig. 5a).         
For iPSC generation, we used a non-viral and non-integrating method 
based on electroporation of three plasmids encoding for the key 
transcription factors of stem cells: OCT4, SOX2, c-MYC, NANOG, KLF4 
and LIN28 (Fig. 5b). 
During proliferation, cells progressively lost these three plasmids, leading to 
the generation of iPSCs free from vectors and exogenous sequences.     
The iPSCs showed the typical embryonic stem cell morphology, growing as 
colonies in adhesion and forming EBs when re-suspended in low 
attachment conditions. All iPSCs expressed markers of pluripotency such 
as SSEA4, TRA1-60, TRA1-81, SOX2 and OCT4 (Fig. 5c). 
iPSCs maintained euploid karyotipe and could differentiate into all three 
germ layers (ectoderm, mesoderm and endoderm) both in vitro and in vivo, 
forming teratomas after transplantation into immunodeficient mice (data not 
shown).  
Once we generated and fully characterized our iPSC line, we differentiated 
it into NSCs using a multistage protocol optimized to allow the generation of 
a neuronal fate. This protocol allowed us to generate a high percentage of 
neuroepitelial cells positive for NSC and precursor markers such as PAX6, 
SOX2 and Nestin (>90%). 
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Fig. 5 Generation of human iPSCs. 
(a) Schematic representation of the non-viral, non-integrating reprogramming method used 
for iPSC generation starting from control skin fibroblasts. (b) Maps of episomal vectors 
encoding for pluripotency transcription factors such as OCT4, SOX2, c-MYC, NANOG, KLF4 
and LIN28. (c) Colonies of iPSCs in adhesion conditions. In the first panel, a colony of 
iPSCs in bright field; in other panels, immunocytochemistry characterization of this control 
iPSC line, which expressed the typical markers of pluripotency, SSEA4, TRA1-60, TRA1-81, 
SOX2 and OCT4 (in green). Scale bar: 75 µm (SOX2 65 µm). In blue, nuclei stained with 
DAPI. 
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4.2 Selection of LeX+CXCR4+β1+ NSCs and characterization 
After differentiation of iPSCs into NSCs via EBs (Fig. 6a), we employed a 
combination of immunomagnetic (MACS) and fluorescence-activated cell 
sorting (FACS) analysis in order to select the subpopulation of NSCs 
positive for Lewis X, CXCR4, and β1 integrin (Fig. 6).  
Since preliminary analyses of these three markers revealed a relative low 
percentage of cells positive for CXCR4, we enriched our NSC line for the 
CXCR4+ population using MACS. Enriched cells were later analyzed by 
FACS, which showed an increased percentage (81.4%) of CXCR4+ NSCs 
(Fig. 6b). 
After plating and expansion, CXCR4+ cells were further selected by FACS 
for β1 integrin (or CD29), LewisX (LeX or CD15) and CXCR4 positivity. 
FACS re-analysis showed an enrichment of NSCs positive for the three 
markers (Fig. 6c). 
After LeX+CXCR4+β1+ NSC selection, we further expanded them in 
neuronal media supplemented with fibroblast growth factor (FGF)-2 in 
adherent conditions and we fully characterized them (Fig. 7). 
Immunocytochemistry confirmed the expression of the three markers (Fig. 
7a). The expression of the typical antigens of NSCs, such as PAX6, SOX2 
and Nestin (Fig. 7b) confirmed the neural property of this subpopulation. 
The cells maintained also their multipotency and were able to differentiate 
into neurons, astrocytes, and oligodendrocytes (Fig. 7c). 
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Fig. 6 NSC generation and selection for Lewis X, CXCR4 and β1 integrin. 
(a) NSC generation: iPSC colonies were detached and maintained in suspension in order to 
form EBs, which were treated with neuronal medium. The dissociation of EBs allowed NSC 
formation in appropriate neuronal media. (b) FACS analyses revealed a high percentage of 
CXCR4+ NSCs after MACS sorting (81.4% of CXCR4+ NSCs). (c) Selection of NSCs for 
their positivity for the three markers: Lewis X (or CD15), CXCR4 and β1 integrin (or CD29).  
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Fig. 7 Characterization of LeX+CXCR4+β1+ NSCs. 
(a) Immunocytochemistry of the FACS selected triple positive subpopulation of NSCs for the 
three markers, Lewis X (in green), CXCR4 and β1 integrin (in red). (b) NSCs expressed the 
marker of NSCs like PAX6, SOX2 (in green) and Nestin (in red) and (c) could differentiate 
into neurons (TuJ+, in green), astrocytes (GFAP+, in green) and oligodendrocytes (O4+, in 
red). Nuclei are stained in blue with DAPI. Scale bar: 100 µm LeX; 70 µm CXCR4; 75 µm 
β1; 65 µm PAX6; 50 µm SOX2; 70 µm Nestin; 50 μm in the (c) panel. 
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4.3 LeX+CXCR4+β1+ NSC transplantation in SOD1G93A mice 
We evaluated the ability of LeX+CXCR4+β1+ NSCs to engraft the spinal 
cord and to migrate through the host nervous system parenchyma by 
tracking them with the GFP reporter. 
One million of cells were administered into the cerebrospinal fluid (CSF) by 
intrathecal injection into the SOD1G93A transgenic mice, the ALS model 
that carries high copy number of human SOD1 gene with the G93A 
mutation (Fig. 8a). One month after administration, we observed a relevant 
engraftment of donor cells GFP positive in the host parenchyma (Fig. 8b). 
Some transplanted cells were able to differentiate into mature neurons and 
MNs, as revealed by co-localization of TuJ1 or Smi32 and GFP reporter 
respectively (Fig. 8 b, c). 
Analyzing the entire spinal cord, we observed that the major part of GFP+ 
NSCs was localized in the lumbar spinal cord closed to the site of injection. 
However, a relevant number of cells were detected also in both cervical 
and thoracic spinal cord (Fig. 8d). In particular, we observed clusters of 
NSCs in the anterior horns area of the spinal cord, where MNs are actively 
degenerated. After transplantation, we also characterized the phenotypic 
fate of donor cells. We observed that the vast majority of transplanted cells 
maintained neural stem phenotype, as demonstrated by a consistent 
portion of GFP positive cells expressing Nestin, the NSC marker (Fig. 8e). 
Only a small percentage of donor cells differentiated into mature neurons 
and microglial cells. Among donor cells that acquired glial commitment, we 
observed a more relevant differentiation of NSCs into astrocytes compared 
to oligodendrocytes, which were less than 5% (Fig. 8e). 
Transplantation of NSCs did not cause adverse effects like tumors or 
abnormal cell proliferation. No inflammation was observed in treated mice. 
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Fig. 8 Transplantation of LeX+CXCR4+β1+ NSCs into ALS mice. 
(a) Representative illustration of the in vivo experiments: selected NSCs were intrathecally 
administered in the ALS mouse model (SOD1G93A) at 90 days of age. One month after, 
spinal cords of treated mice were analyzed. (b) Immunohistochemistry revealed that GFP+ 
NSCs (in green) were able to differentiate into neurons (TuJ1+, in red) in the host spinal 
cord. (c) Donor cells GFP+ were also able to differentiate into MNs as shown by their 
positivity for Smi32 (in red). (d) Quantitative analysis of GFP+ NSCs in the spinal cord 
revealed transplanted cells in the entire spinal cord. In fact, GFP+ NSCs were detected in 
cervical, thoracic and lumbar spinal cord. (e) Quantitative analysis of the phenotypic fate of 
engrafted cells showed that a significant portion maintained the neural stem/precursor 
phenotype (nestin) and a small fraction differentiated into mature neuronal (NeuN) and glial 
(GFAP) phenotypes. Data are shown as mean ± SD. Nuclei are stained with DAPI (in blue). 
Scale bars: 150 µm in (b) panel and 50 µm in (c) panel. 
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4.4 LeX+CXCR4+β1+ NSCs protect MNs, axons and NMJs  
The typical hallmark of ALS consists in a progressive degeneration of MNs.  
For this reason, we performed quantification of MNs in SOD1G93A mice at 
120 days of age of NSC-treated mice and controls, which were treated with 
fibroblasts or saline solution (vehicle). The results of NSC transplantation 
consisted in a significantly reduction of MN death compared to vehicle-
treated SOD1G93A mice (P < 0.05) (Fig. 9 a, c). Furthermore, we observed 
a preservation of axons after NSC treatment. The analysis of lumbar L4 
ventral roots, revealed an higher number and size of axons in NSC-treated 
SOD1G93A mice at 120 days (P < 0.05) (Fig. 9 b, d).  
The preservation of MNs and their axons had a significant effect on NMJs. 
We observed a delay in term of NMJs denervation in NSC-treated 
SOD1G93A mice respect to animals treated with vehicle (Fig. 9 e, f). 
Moreover, NSC-treated mice showed an almost preserved number of intact 
pretzel-shaped NMJs (Fig. 9g). In NSC-treated mice, the fully innervated 
NMJs were 65.2 ± 5.7 % compared to 21.8 ± 4.9 % in controls (P < 0.01) 
(Fig. 9g). Also, we noticed a relevant reduction in term of completely or 
partially denervated NMJs compared to SOD1G93A mice treated with 
vehicle. 
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Fig. 9 Transplantation of LeX+CXCR4+β1+ NSCs protects MNs, axon and NMJs. 
(a) Nissl-staining on spinal cords of WT and affected mice treated with vehicle or NSCs.     
(b) Toluidine blue staining performed on spinal cords of all three animal groups.                      
(c) Quantitative analyses of MNs in the lumbar spinal cord at 120 days of age. ALS mice 
treated with NSCs showed an increased number of MNs compared to controls. Data are 
mean ± SD (*P < 0.05, ANOVA). (d) Axon quantification showed a higher number in NSC-
treated mice compared to controls. We considered 6 animals per group at 120 day of age. 
Data are mean ± SD (*P < 0.05, ANOVA). (e) Staining on anterior tibialis (TA) muscles with 
post-synaptic α-bungarotoxin (in red) and pre-synaptic 2H3 (in green). (f) Quantitative 
analyses of NMJs in the TA muscles showed an increased percentage of NMJs in NSC-
treated mice (**P < 0.01, ANOVA, n=6, data are mean ± SD). (g) Qualitative analyses of 
NMJs revealed an increased number of distinct NMJs compared to controls and a reduction 
of devoid NMJs (**P < 0.01, ANOVA, n=6, values are mean ± SD). Scale bar: (a) 100 µm; 
(b) 75 µm; (e) 50 µm.  
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4.5 NSC transplantation improves ALS phenotype and survival 
We investigated the therapeutic potential of LeX+CXCR4+β1+ NSCs on 
muscular function and survival in SOD1G93A mice. 
Mice treated with NSCs showed an increased muscle strength compared to 
controls, as demonstrated by the inverted grid assay (P < 0.05, Fig. 10a). 
SOD1G93A mice treated with vehicle were progressively weaker and 
unable to move with the disease progression. Vice versa, SOD1G93A mice 
treated with NSCs appeared healthier and were able to walk and explore 
the cage. These evidences support the positive effects of NSC 
transplantation on neuromuscular phenotype. 
Remarkably, we observed a significant increase in the survival of NSC-
treated mice. In fact, the average of life span was 165 ± 5 days for NSCs-
treated animals (n=12) and 142 ± 11 days (n=15) for vehicle-treated mice 
(Chi-square for equivalence of death rates= 14.32, P = 0.0002, Kaplan–
Meier log rank test for survival) (Fig. 10b).  
 
Fig. 10 Improvement of neuromuscular function and survival in ALS mice treated with 
LeX+CXCR4+β1+ NSCs. 
(a) NSC transplantation determined amelioration of neuromuscular function as 
demonstrated by inverted grid hanging assay showing an improved ability of NSC-treated 
mice (*P < 0.05, ANOVA). (b) Kaplan-Meyer survival curves for ALS mice treated with NSCs 
or vehicle. The survival was increased in NSC transplanted mice (P = 0.0002, log-rank test). 
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4.6 LeX+CXCR4+β1+ NSCs reduce macro- and micro- gliosis 
During disease progression, reactive astrocytes and microglial cells 
accumulate in the spinal cord of ALS patients and animal models.               
These findings support the relevance of non-autonomous component in 
ALS pathogenesis [82]. For this reason, we investigated whether NSCs 
were able to reduce astrocytosis, the abnormal proliferation of toxic 
astrocytes. In particular, we detected a significant reduction of reactive 
astrocytosis after NSCs transplantation. Indeed, GFAP and s100β staining 
revealed a significantly reduction of astrocytes in the spinal cord 
parenchyma of NSC-treated mice compared to vehicle-treated SOD1G93A 
mice (P < 0.05) (Fig. 11 a, c). We also observed a significant reduction in 
microglia cells (Iba1+) in the spinal cord of NSC-treated SOD1G93A 
respect to controls (P < 0.05) (Fig. 11 b, d). 
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Fig. 11 Macro- and micro- gliosis analysis. 
(a) Immunostaining with GFAP and s100β for macrogliosis and (b) with Iba1 for microgliosis 
in all three animal groups (WT, SOD1G93A mice treated with vehicle, SOD1G93A mice 
NSC-treated). Nuclei are in blue stained with DAPI. Glial markers are in red. (c) 
Quantification of astrocytes in spinal cord revealed a reduction of astrocytosis in NSC-
treated mice. (d) Number of microglial cells was diminished in the spinal cord of NSC-
treated mice. All data are shown as mean ± SD.* P < 0.05, ANOVA. Scale bar: 150 µm. 
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4.7 NSCs exert beneficial effects reducing GSK3β  
It has been demonstrated that abnormal increase in levels and activity of 
GSK3β, a serine/threonine protein kinase, are associated with MN death 
[93, 169] and that its inhibition protects MNs from degeneration [173-175]. 
In order to investigate the possible molecular mechanisms by which 
LeX+CXCR4+β1+ NSCs exert their beneficial effects in ALS mice, we 
analyzed level of GK3β kinase in spinal cord of our cohort of mice.      
Western blot analyses revealed an increase of 2-folds in GSK3β expression 
in ALS mice compared to WT animals. Despite treatment with NSCs 
determined a reduction of GSK3β protein in spinal cord of affected mice, 
this reduction is not statistically significant (Fig. 12). 
 
 
 
Fig. 12 Levels of GSK3β in spinal cord. 
(a) Western blots analysis of GSK3β and β-actin in the spinal cord of all three groups of 
mice. (b) Densitometry analyses of the GSK3β expression in spinal cord of WT and 
SOD1G93A mice treated with vehicle or LeX+CXCR4+β1+ NSCs. When normalized for β-
actin protein expression, there was significant difference in GSK3β expression between WT 
and ALS mice (* P < 0.05). However, no difference occurs between ALS mice treated with 
vehicle or NSCs.  
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4.8 LeX+CXCR4+β1+ NSCs protect human ALS MNs in vitro  
To investigate whether NSCs exert a therapeutic effect also in a human in 
vitro model of ALS, we employed a co-culture assay using iPSC-derived 
MNs, murine ALS astrocytes and LeX+CXCR4+β1+ NSCs (Fig. 13a).     
First of all, to generate spinal MNs from control and ALS iPSC lines, we 
used a multistep protocol based on RA and Shh [109]. After 4 weeks of 
differentiation conditions, cells expressed the typical markers of MN such 
as Smi32 and Hb9 (Fig. 13b) and also pan-neuronal markers such as TuJ1, 
Neurofilament, and MAP2 were observed (data not shown). Since the 
protocol of differentiation yielded a mixed cell population, we enriched MN 
population applying a physical strategy based on gradient centrifugation. 
Then, iPSC-derived MNs from both control subjects and ALS patients were 
co-cultured with toxic ALS astrocytes derived from SOD1G93A mice. 
Before plating with ALS astrocytes, both control and affected iPSC-derived 
MNs were visualized by a lenti-Hb9::eGFP construct, appeared control and 
showed elongated processes (Fig. 13c). On the contrary, when plated with 
ALS toxic astrocytes, iPSC-derived MNs progressively degenerate after 20-
23 days of culture (Fig. 13 c, d). In particular, MNs derived from both 
familial and sporadic ALS patients were more sensitive to the toxicity of 
ALS astrocytes compared to control MNs (P < 0.01, Fig. 13d). However, 
when NSCs were added to the co-culture, we observed a significant 
protection of MNs. In fact, when exposed to LeX+CXCR4+β1+ NSCs, 
iPSC-derived MNs were significantly spared (P < 0.01) (Fig. 13d). 
Therefore, our findings demonstrate that NSCs can protect affected MNs 
from degeneration in an ALS-like toxicity system. 
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Fig. 13 LeX+CXCR4+β1+ NSCs protect human MNs in vitro. 
(a) Schematic representation of co-culture assay, which consisted in human control and ALS 
iPSC-derived MNs (in green) and murine SOD1G93A astrocytes (in red). In this type of co-
culture, also selected NSCs were plated (in bright field). (b) MNs derived from differentiation 
of human iPSCs. In the first panel, iPSC-MNs in bright field, other panels showed the 
expression of the typical markers of MNs like Smi32 and Hb9 (in green). (c) Before plating 
MNs with astrocytes in our co-culture system, iPSC-derived MNs were labeled with the 
construct lenti-Hb9::eGFP and stained with Smi32 in red (first panel in c). As showed in the 
second panel, the number of iPSC-derived MNs was reduced when plated with SOD1G93A 
astrocytes. However, the presence of NSCs in the co-culture determined a preservation of 
MNs exposed to astrocytes toxicity (last panel in c). Nuclei stained in blue with DAPI. (d) MN 
quantification in different conditions: MNs plated with control or ALS astrocytes and with or 
without NSCs. Quantification revealed a decreased number of MNs after co-culture with 
SOD1G93A astrocytes (**P < 0.01, ANOVA), however the presence of NSCs improved MNs 
survival (**P < 0.01, ANOVA). Data are means ± SEM from 5 experiments in triplicate. Scale 
bar: 50 µm (Hb9 70 µm).  
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4.9 NSCs protect human MNs by inhibiting GSK3β activity 
In this human in vitro ALS model, we analyzed the putative mechanisms of 
neuroprotection induced by NSCs. Since increased levels of GSK3β were 
found in spinal cord of ALS mice, we analyzed the role of this kinase also in 
vitro. Abnormal levels or hyper-activation of GSK3β determines death of 
MNs. Based of these findings, we analyzed GSK3β activity in iPSC-derived 
MNs. Inactivation of GSK3β is determined by a specific phosphorylation in 
Ser9. For this reason, we evaluated Ser9-site specific phosphorylation of 
GSK3β (GSK-3PSe9) in iPSC-MNs from ALS and control subjects. Anti-
Phospho GSK3β immunocytochemistry revealed that levels of GSK-3PSe9 
phosphorylation were reduced in ALS MNs compared to control MNs. 
However, when exposed to NSCs, affected MNs showed higher levels of 
GSK-3PSe9 (P < 0.01). This data indicate that NSC treatment determined 
an inactivation of GSK3β in ALS MNs, protecting them from degeneration 
(Fig.14). 
 
Fig. 14 NSCs increased phosphorylation of GSKβ in human MNs. 
(a) Staining of Ser9 phosphorylation in the GSK3β enzyme (red signal), in absence (left) or 
presence (right) of NSCs. In blue, nuclei stained with DAPI. (b) Quantitative analysis of 
GSK-3PSe9 showed a significant difference in the phosphorylation level (** P < 0.01). MNs 
were labeled with Hb9-GFP (green). Scale bar: 75μm. 
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4.10 NSCs protect MNs by producing neurotrophic factors 
In neurodegenerative diseases like ALS, NSCs can be potentially 
therapeutic through multiple mechanisms, which include not only neuronal 
replacement but also bystander effects such as the production and delivery 
of neurotrophic factors. In fact, we and other groups observed that NSCs 
induce neuroprotection thanks to their ability to deliver neuroprotective 
molecules [110, 165, 176]. Here, we noticed that NSCs released a wide 
spectrum of neurotrophic factors and molecules that promote neurite 
outgrowth. In particular, our subpopulation of NSCs produced glial cell-
derived growth factor (GDNF), brain-derived neurotrophic factor (BDNF), 
neurotrophin-3 (NT3), and transforming growth factor alpha (TGF-α) 
(versus human fibroblasts; P < 0.001) (Fig. 15). 
 
Fig. 15 NSCs produce high levels of neurotrophic factors. 
(a-d) ELISA test showed that LeX+CXCR4+β1+ NSCs (LCB NSCs+) released higher level 
of neurotrophic factors, such as GDNF, BDNF, NT3 and TGF-α, compared to NSCs 
negative for the three markers (LCB NSCs-) and fibroblasts. All data are mean ± SD (* P < 
0.05; ** P < 0.01). 
Results 
 
76 
 
4.11 NSCs inhibit ALS astrocytes proliferation activating TRPV1 
We evaluated the effect of LeX+CXCR4+β1+ NSCs on astrocytes 
proliferation (Fig. 16).  
We already showed that SOD1G93A astrocytes exposed to molecules 
secreted by human ALDH NSCs significantly diminished their vitality [110]. 
In particular, astrocytes proliferation was reduced by endovanilloids 
secreted by NSCs that bind the TRPV1 receptor on astrocytes. Thus, we 
hypothesized a suppressor function on ALS toxic astrocytes of the 
endovanilloids produced by NSCs [110].  
Here, we investigated if this event occurs also with LeX+CXCR4+β1+ 
NSCs. We demonstrated that astrocytes derived from SOD1G93A mice 
were TRPV1 positive (Fig. 16a) and the addition of LeX+CXCR4+β1+ 
NSCs in culture induced astrocytes death (Fig. 16b). Selective inhibitors of 
TRPV1, like iodoresiniferatoxin (I-RTX) or capsazepine (CZP), reduced 
NSC cytotoxicity on ALS astrocytes (Fig. 16c). These data show that 
LeX+CXCR4+β1+ NSCs cause inhibition of ALS toxicity by activating 
TRPV1. 
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Fig. 16 LeX+CXCR4+β1+ NSCs inhibit astrocytes proliferation via TRPV1 activation. 
(a) Expression of GFAP (green) and TRPV1 (red) in WT astrocytes (upper panel) and in 
SOD1G93A astrocytes (lower panel). In blue, the nuclei stained with DAPI. Scale bars: 30 
μm on the left and 10 μm in the right image with higher magnification. (b) Level of TRPV1 
was higher in SOD1G93A astrocytes respect to WT astrocytes as quantified in the graph 
with relative fluorescence intensity (* P < 0.05). (c) The survival of SOD1G93A astrocytes 
was reduced when exposed to LeX+CXCR4+β1+ NSC–conditioned medium. (d) Inhibition 
of TRPV1 with I-RTX and CZP determined a reduction of the LeX+CXCR4+β1+ NSCs 
cytotoxicity on astrocytes, indicating that the beneficial action of LeX+CXCR4+β1+ NSCs is 
mediated by activation of TRPV1. All results are shown as mean ± SD. *P < 0.05, **P < 
0.01; Student's t-test. 
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5. DISCUSSION 
 
ALS, also known as Lou Gehrig’s disease, is a neurodegenerative disorder 
that affects MNs, the nerve cells involved in the transmission of the 
electrical impulses from brain to the muscles [1]. In ALS, MNs in the spinal 
cord, brainstem and cortex undergo to a progressive degeneration and 
death, determining a loss of the capacity to initiate and control voluntary 
movements. The consequence of MN degeneration is a progressive 
paralysis and muscle atrophy. Despite muscle weakness and paralysis are 
universally experienced, the onset of ALS is variable and could starts in 
muscles that control legs, feet, arms, hands, speech or swallowing.           
Among MN diseases, ALS is the most common and severe form in adults; 
in fact, ALS is particularly aggressive determining death of patients in 3-5 
years from the onset of the first symptoms [4]. Currently, there is no 
effective cure for ALS beyond supportive care and Riluzole, which extends 
median survival only by about 2 to 3 months. 
Because causes and mechanisms involved in ALS are largely unknown, 
the way to find a cure is particularly difficult. Indeed, ALS is a complex 
disorder involving an intricate combination of events including genetic, 
environmental and lifestyle factors [17]. Moreover, a wide spectrum of 
molecular and cellular mechanisms has been proposed to mediate the 
progressive MN degeneration in ALS. Besides, to complicate matters 
further, different cell types contribute to the development of this pathology, 
that include beside MNs, other neurons, astrocytes, microglia and 
oligodendrocytes. 
 
 
 
Discussion 
 
79 
 
Given the multifaceted nature of this neurodegenerative disorder, the 
therapeutic strategies that targeted only one specific pathogenetic disease 
aspect likely will have minimal impact on ALS phenotype [101].                  
On the contrary, approaches that affect many pathophysiological 
mechanisms at the same time could have a better efficiency.                  
For this reason, stem cell transplantation has recently become an attractive 
option thanks to its multiple actions that can influence simultaneously many 
different pathogenetic events. In fact, although the initially proposed 
mechanism was cell replacement, now it is clear that stem cells may also 
provide a large number of benefits by modulating the micro-environment, 
leading to a reduction of inflammation and protecting MNs and neuronal 
circuitry [148].  
Among the different stem cell sources, NSCs are particularly appropriate 
for ALS treatment due to their capability to primarily differentiate into 
neuronal and glial cells, providing a valuable life-long source of nervous 
cells. Moreover, since NSCs are more specialized and differentiated than 
embryonic stem cells, the risk of forming tumors after transplantation is 
reduced. The positive effects of NSC transplantation have been already 
demonstrated in pre-clinical experiments and it is now being explored in 
clinical trials. In fact, when transplanted into the spinal cords of ALS animal 
models, NSCs derived from embryonic stem cells or iPSCs determined an 
effectively improvement in term of survival and pathological phenotype 
[110, 165]. Besides, a phase I clinical studies revealed that NSC 
transplantation via intraspinal cord injections in ALS patients is safe and 
also seems to partially reduce disease progression, even if the therapeutic 
effect was not principal aim of the trial [166, 167]. 
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In our in vitro and in vivo experiments, we used a control cell line of NSCs 
derived from iPSC differentiation. Since iPSCs are directly derived from 
adult tissues, they not only bypass ethical issue of the embryo manipulation 
but are also they are patient-specifics, meaning that they can potentially 
reproduce the ALS features in vitro. For these reasons, the iPSC 
technology is promising for both cell transplantation and for modeling 
human pathologies in vitro. In this study, the iPSCs were generated by 
reprogramming differentiated adult cells to a state of pluripotency, through 
the expression of transcription factors using a non-viral and non-integrating 
technique. We reprogrammed fibroblasts derived from skin biopsies of a 
control subject performing electroporation of plasmids, which encode for 
the key transcription factors of stem cells such as OCT4, SOX2, c-MYC, 
NANOG, KLF4, and LIN28 [104, 109-111]. We isolated a control iPSCs line 
that showed the embryonic stem cell morphology and expressed the typical 
markers of pluripotency like SSEA 3 and 4, TRA1-81, TRA1-60, OCT4 and 
SOX2. In addition, further analyses revealed that iPSCs maintained euploid 
karyotype and their ability to differentiate into all three germ layers both in 
vitro and in vivo.  
Once generated and characterized, iPSCs were differentiated into NSCs 
using a multistage protocol, which consisted in EB formation and treatment 
with small molecules to induce neuralization. This technique was optimized 
in order to generate a high percentage of neuronal fate cells; in fact, more 
than 90% of cells were positive for PAX6, a NSC marker [110].  
Since the efficiency of cell transplantation can be limited by a reduced 
ability of cells to migrate and reach the affected areas, we selected a 
subpopulation of NSCs in order to increase their ability to engraft and 
migrate through the nervous system parenchyma, to protect degenerating 
MNs and to improve ALS phenotype. In particular, we sorted NSCs for the 
presence of three markers: Lewis X, CXCR4 and β1 integrin.                  
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These three markers were crucial for migration and engraftment of 
transplanted NSCs for the following reasons:  
- Lewis X, also called CD15 or SSEA-1, is an adhesion molecule expressed 
on cell surface and it is one of the most important ligand of receptors 
present on endothelial cells [177]. It is also a marker of pluripotent stem 
cells and plays a relevant role in cell migration and adhesion in the pre-
implantation embryo [178]. In particular, Lewis X mediates the 
extravasation of cells positive for this marker and increases the ability of 
cells to migrate through the spinal cord. 
- CXCR4 is a chemokine receptor, which increases the sensitivity of the 
cells to be recruited by the host diseased spinal cord that produces 
chemoattractant cytokines. During embryogenesis, CXCR4 is expressed by 
newly generated neurons. In adult life, it plays a role in neuronal guidance. 
It also seems to be involved in the adhesion phase of human embryonic 
implantation. Cells positive for CXCR4 could migrate from cerebrospinal 
fluid (CSF), that bathes the entire central nervous system, to spinal cord 
thanks to proinflammatory cytokines, which are produced by injured central 
nervous system (CNS). Among molecules produced by sites of damage, 
the SDF1 alpha (or CXCL12) is one of the chemokines recognized by 
CXCR4+ cells [179]. 
- β1 integrin is a subunit of VLA4, a receptor that allows cells to cross the 
blood-brain barrier, particularly in the presence of inflammation as in ALS 
animal models and human patients. Also the β1 integrin played a critical 
role in NSCs migration from CSF to the parenchyma. In fact, in association 
with alpha 4 integrin, β1 integrin form a cell surface receptor that binds 
VCAM on endothelium activated by inflammatory signals and mediates the 
cell extracellular matrix interaction allowing the migration [180].  
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In addition, since β1 integrin is a NSC marker, cells positive for this marker 
showed a more neuralized phenotype and an increased ability to 
differentiate in neurons and not in other cell types. 
In our work, NSCs positive for LeX, CXCR4 and 1-integrin were 
transplanted in the most widely used mice model of ALS, the SOD1G93A 
mice. This transgenic mouse, which carries multiple copies of human SOD1 
gene with G93A mutation, recapitulates most of the typical hallmarks of 
familial and sporadic ALS patients [67]. In fact, SOD1G93A mouse model 
develops ALS symptoms like muscle atrophy and progressive paralysis at 
day 80-90, causing death at 140 days of age. Moreover, histological 
analyses reflect the neuropathological findings of ALS patients such as 
SOD1 protein aggregation, reduced number of MNs and roots, and macro- 
and micro-gliosis [69].  
Our subset of NSCs was administered into SOD1G93A ALS mice 
performing intrathecal injections. Compared to systemic routes (intravenous 
and epidural injections), intrathecal injections allow the direct administration 
of cells to CSF and is far less invasive compared to local 
intracerebroventricular administrations. In fact, lumbar puncture is a 
common clinical minimal invasive procedure used for diagnostic and 
therapy in some neurological conditions. 
In order to improve the clinical translation of this approach, the 
transplantation of NSCs was performed in ALS animal model after the 
onset of symptoms, although in an early symptomatic stages. 
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After intrathecal injection into the SOD1G93A transgenic mice, we analyzed 
whether this subpopulation of NSCs LeX+CXCR4+β1+ were able to 
properly engraft and migrate through the host nervous system parenchyma. 
We noticed that a relevant number of NSCs were engrafted in the host 
parenchyma. In particular, NSCs were localized in the lumbar spinal cord, 
near the site where the injections were performed, and also in both cervical 
and thoracic spinal cord, far from the site of injection. We also observed 
clusters of NSCs in the anterior horns area of the spinal cord, where MNs 
are actively degenerated. Thanks to their ability to differentiate into 
neuronal and glial cells, transplanted cells contributed to the host central 
nervous system pool constitution, although, the majority of transplanted 
cells maintained their undifferentiated neural stem phenotype.  
Moreover, NSC transplantation was safe as revealed by absence of 
adverse effects like tumors, abnormal cell proliferation or 
neuroinflammation in treated mice. These data revealed the safety of this 
treatment and the ability of this NSC subset to bypass the blood brain 
barrier, reaching the spinal cord, and migrate through the parenchyma 
where in minimal part differentiate and contribute to neuronal pool.    
Neuropathological analyses performed in affected mice at 120 days of age 
revealed that mice treated with NSCs showed an increased number of MNs 
and axons, higher size of nerves and preservation in NMJs. In particular, 
we noticed that NSC treatment determined an augmentation of NMJs fully 
innervated, meaning that these NMJs are functionally active. Furthermore, 
NSCs determined a reduction in the number of inactive or devoid NMJs. 
These findings revealed that NSCs exerted a therapeutic effect on ALS 
neuropathology by protecting MNs and their axons. In particular, this 
beneficial effect was at the proximal central level and also in the periphery, 
preserving the NMJs. In fact, at 120 days, the NSCs-treated SOD1G93A 
mice presented a significant improvement in NMJ innervations.  
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Interestingly, since the number of preserved NMJs was higher compared to 
the number of protecting MNs, these findings suggest that NSC 
transplantation in ALS mice model induced the formation and maintenance 
of terminal axon sprouts in the surviving MNs in order to preserve NMJs 
innervations. Along the disease progression in transplanted SOD1G93A, 
the preservation of NMJ innervations, by maintaining their integrity and 
inducing axonal sprouting, correlated with an improved neuromuscular 
phenotype, and increased survival. In fact, compared to SOD1G93A mice 
treated with vehicle, NSC-treated animals looked healthier, were able to 
walk and explore the cage and showed a relatively improving in muscle 
strength, as shown by a delay to incomplete the inverted hanging grid test. 
The improving in neuromuscular phenotype determined by transplantation 
of LeX+CXCR4+β1+ NSCs was associated with 16% of increased survival. 
Next, we analyzed the putative mechanisms involved in neuroprotection 
determined by our subpopulation of NSCs. It is already established that 
NSCs can be therapeutic through multiple mechanisms, which include 
modulation of the micro-environment, reduction of inflammation, protection 
of MNs and neuronal circuitry and eventually cell replacement [148]. 
We found that LeX+CXCR4+β1+ NSCs exerted positive effects through 
autonomous mechanisms on MNs and non-autonomous actions that can 
significantly contribute to MN death in which astrocytes and microglial cells 
that surround MNs are involved. 
Between autonomous mechanisms, our subset of NSCs determined MN 
protection by modulation of GSK3β pathway.  
GSK3α and GSKβ are serine/threonine kinases involved in glycogen 
metabolism, gene transcription, apoptosis and microtubule stability [181].  
In the nervous system, both isoforms of GSK3 are detected in pre and post 
synapses and are involved in proliferation, differentiation and 
neurotransmission in adult neurons [90].  
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In particular, GSK3β has been identified as one of the principal enzymes 
involved in neuronal cell death in ischemic stroke and some 
neurodegenerative disorders like Parkinson’s disease, Alzheimer’s disease 
and ALS [182-184].  
Interestingly, in these pathological conditions, both level and activity of 
GSK3β are found increased. The precise mechanisms that induce the 
hyperactivation and overexpression of GSK3β remain to be elucidated. 
Since GSK3β is a constitutively active kinase, it seems that the disturbance 
of signaling proteins upstream of GSK3β could alter its activity and level, 
resulting in activation of apoptotic pathway.  
It is hypothesized that excessive stresses acting on neurons could reduce 
the activation of PI3K, a kinase that normally phosphorylates and activates 
Akt. Once active, the Akt determines the phosphorylation of GSK3β in the 
amino-terminal serine 9 residue (Ser9), causing inhibition of its kinase 
activity. For this reason, some pathological conditions determine an 
increase in the active form of GSK3β. When hyperactivated or 
overexpressed, GSK3β determines a series of events involved in a variety 
of cellular processes. Among its substrates, CCAAT/enhancer binding 
protein, Myc, HSTF-1, the nuclear factor of activated T cells, β-catenin, 
cyclic AMP response element binding protein, tau, activator protein-1, 
NFkB, p53, release of cytochrome c and caspase-3 are directly affected by 
GSK3β [182, 184-188]. These processes result in death of neurons via 
activation of the mitochondrial apoptotic pathway.  
Many studies showed that GSK3β expression and activity were increased 
in ALS MNs. In vitro, level of GSK3β are increased after transfection of 
MNs with mutant human SOD1 genes and also in vivo, level of this kinase 
is increased in the spinal cord of the ALS mice model.  
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Interestingly, specific inhibitors, like lithium and valproate, or using 
materials with GSK3β inhibitory effects reduced death of SOD1 MNs in vitro 
[189] and increased survival in ALS mouse models [175]. 
The putative mechanisms of protection determined by GSK3β inhibition 
consist in reducing death-related signals, such as cytochrome c, thereby 
reflecting mitochondrial injury, activated caspase-3, and cleaved forms of 
poly (ADP-ribose) polymerase; by restoring survival-related signals, such 
as HSTF-1; by decreasing inflammation-related signals such as 
cyclooxygenase-2 and intercellular adhesion molecule 2.  
On the light of these findings, one of the possible mechanisms by which 
NSCs induce protection of MNs could be due to reduction of GSK3β level in 
spinal cord. For this reason, we analyzed level of GSK3β in the spinal cord 
of our cohort of mice (WT, ALS treated with vehicle or selected NSCs).              
Our preliminary results confirmed what observed in literature; in fact, level 
of GSK3β was significantly increased in the spinal cord of ALS mice 
compared to wild type. Despite not statistically relevant, transplantation of 
NSCs in affected mice seems to reduce level of GSK3β in spinal cord 
respect to treatment with vehicle only. Although to be confirmed, these data 
suggests that one of the putative mechanisms of NSC protection within 
MNs could be restoration of physiologically levels of GSK3β. 
Among beneficial effects exerted by NSC transplantation, the reduction of 
macro and micro gliosis is one of the mainly effects. It is already 
demonstrated that in ALS, degenerating MNs release neurotoxic molecules 
that stimulate astrocytes and microglia to produce toxic proteins and pro-
inflammatory cytokines, resulting in MN damage and initiating the vicious 
cycle of progressive cell death [84]. For this reason, we analyzed the effect 
of transplantation of LeX+CXCR4+β1+ NSCs on macro and micro glia.     
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Transplantation of our NSC subset in ALS mice resulted in a significant 
reduction of reactive astrocytosis as revealed by reduced cells positive for 
astrocytes markers like GFAP and s100β. Furthermore, we observed a 
significant reduction in microglia cells (Iba1 positive) in the spinal cord of 
NSC-treated SOD1G93A respect controls. 
Overall, these findings suggest that NSCs transplantation has a positive 
effect on ALS phenotype by reverting the toxic micro-environment of murine 
ALS spinal cord, which can be lead to a relevant therapeutic impact. 
To investigate whether NSCs exert a therapeutic effect also in a human in 
vitro model of ALS, we employed a co-culture assay using iPSC-derived 
MNs and ALS astrocytes derived from SOD1G93A mice model.                   
In this study, MNs were generated from differentiation of iPSCs obtained 
from skin fibroblasts of control and ALS patients (both sporadic and 
familial).  
Promising for autologous cell therapies, the patient-specific iPSCs could be 
important tool to model human diseases in vitro, allowing a better 
comprehension of pathological mechanisms involved in ALS.                  
Both control and affected MNs derived from differentiated iPSCs undergo to 
degeneration when plated with astrocytes of SOD1G93A mice.                  
It has been demonstrated that MN death is caused by multiple toxic effects 
exerted by affected astrocytes. In ALS, astrocytes release toxic molecules 
and are no more able to produce neurotrophic factors and to up-take the 
glutamate causing neuro-excitotoxicity. The toxic effect of ALS astrocytes 
on MNs is confirmed in our co-culture system and, interestingly, MNs 
derived from iPSC lines of ALS patients are more vulnerable to astrocytes 
toxicity compared to control MNs. However, when NSCs were plated in this 
system, iPSC-derived MNs, WT as well as ALS, showed an improvement in 
terms of axonal growth and survival.  
Discussion 
 
88 
 
This finding reveals that LeX+CXCR4+β1 NSCs protect iPSC-MNs from 
toxicity triggered by murine ALS astrocytes in a non-autonomous disease in 
vitro model. 
As above observed in our in vivo experiments performed in ALS mouse 
model, this subpopulation of LeX+CXCR4+β1 NSCs exerts positive effects 
through multiple mechanisms. Among autonomous mechanisms, the direct 
action of our subpopulation of NSCs on affected ALS MNs is due to the 
inhibition of GSK3β and production of neuroprotective factors.                  
Our mechanistic studies of NSC beneficial effects on iPSC-derived MNs 
showed that NSCs in this co-culture system increased GSK3β 
phosphorylation, which determines inhibition of its kinase activity, a feature 
associated with MN survival [125]. 
In addition, our subset of NSCs produce neurotrophic factors such as 
BDNF, GDNF, NT3 and TGFα that could protect MNs from degeneration 
that may be neuroprotective of MNs by paracrine signaling, as our co-
culture results suggest. The link between neurotrophic factors and GSK3β 
activation in MNs could be investigated in the future. 
Finally, we showed that NSCs exerted indirect neuroprotective action 
contrasting the toxic astrocytes effect. In particular, NSCs block the hyper-
proliferation of toxic ALS astrocytes through the activation of the TRPV1 
receptor. TRPV1, transient receptor potential vanilloid-1, is a non-selective 
cation channel expressed on astrocytes surface.  
Previous studies showed that neural and precursor stem cells (NSCs and 
NPCs) released endovanilloids and agonists that directly stimulate the 
endovanilloid receptor, TRPV1. Once activated, TRPV1 not only blocks 
aberrant proliferation of astrocytes and could also induces their death [190].                
Indeed, treatment with TRPV1 antagonists such as iodoresiniferatoxin (I-
RTX) or capsazepine (CZP) determined a reduction in protective effects 
exerted by NSCs.  
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In fact, NSCs induced astrocytes death when plated in our co-culture 
system; however, the addiction of TRPV1 selective inhibitors determined a 
reduction of NSC cytotoxicity on ALS astrocytes. 
Overall, NSCs co-cultured with iPSC-derived MNs and ALS astrocytes 
improved MN survival and increased neurite length acting directly on MNs 
and indirectly contrasting toxic astrocytes effect. 
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6. CONCLUSIONS 
 
Every 90 minutes someone is diagnosed with ALS, which carries a heavy 
clinical, economical, and social burden. Since there is no cure with a 
relevant effect on phenotype, ALS is associated with the urgency of an 
efficient, clinically meaningful therapy for this devastating and fatal disease.  
Among therapeutic approaches for neurodegenerative disorders and ALS, 
NSC transplantation could play a relevant therapeutic role through a 
number of different actions, including production of neurotrophic factors, 
neuroprotection, and preservation of neuromuscular function.                   
These aspects are particularly relevant for ALS treatment since many 
pathological mechanisms appear to contribute in its onset and progression. 
Indeed, NSCs have currently attracted increasing interest as a valid and 
realistic treatment strategy. In particular, iPSCs represent a promising, yet 
unexplored, tool and their differentiation into NSCs may provide an 
important source of multipotent cells to transplant.  
The success of a cellular approach can be achieved by increasing our 
understanding of stem cells features and identification of variables that play 
a major role in the success of transplantation.  
This study contributes to developing a feasible and effective stem cell-
based therapeutic strategy, testing a specific subset of NSCs in ALS animal 
models in order to improve their migratory capacity and efficacy.  
Derived from iPSC differentiation, in our study, NSCs were selected for 
Lewis X, CXCR4 and β1 integrin, markers that increase the engraftment 
and therapeutic potential of stem cells. In fact, here we showed that 
intrathecal administration of LeX+CXCR4+β1 NSCs resulted in an efficient 
engraftment of cells, determining a protection of MNs and their axons from 
degeneration. This correlates with an improvement of the pathological 
phenotype in the ALS rodent model.  
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The therapeutic actions of donor LeX+CXCR4+β1 NSCs comprise 
amelioration of neuromuscular function, increased survival, protection of 
host MNs and positive changes in host-environment such as reduction of 
macro and micro gliosis. In particular, our findings revealed the importance 
of both preserving axon connections with the muscles and enhancing the 
capability of MN to form new NMJs via collateral sprouting to keep 
functional motor unit. 
Moreover, no major side effects like tumors or abnormal cell proliferation 
were observed, confirming the safety of this approach. 
One remarkable aspect of our study consists in a significant positive impact 
of NSC transplantation achieved in animals treated after the onset of 
symptoms, although in an early stages. This is an important aspect given 
the fact that it is likely that human trials will be performed in symptomatic 
phases, requiring slowing of disease progression, rather than preventing 
the disease.  
Furthermore, we observed that this specific subpopulation of NSCs derived 
from human iPSCs, was able to protect affected MNs from degeneration 
not only in ALS mice model but also in a human in vitro model. 
Overall, our results support the rationale and utility of deeply selecting a 
specific NSC population for therapeutic purpose for its impact on MN 
survival. 
The beneficial effect of LeX+CXCR4+β1+ NSCs was achieved targeting 
multiple deregulated cellular and molecular mechanisms in both MNs and 
glial cells in ALS models. 
This aspect is particularly relevant for ALS because many pathological 
mechanisms appear to contribute in its onset, making NSC transplantation 
a promising therapeutic approach for ALS. 
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In conclusion, this study provides evidence that the LeX+CXCR4+β1+ NSC 
subpopulation derived from pluripotent cells are a potentially useful 
therapeutic tool to ameliorate ALS disease phenotype.  
Combining cell transplantation treatment with drug or gene therapy might 
further increase the therapeutic efficacy to a clinically significant level for 
ALS and other MN diseases. 
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